Form: 10-K

Annual report pursuant to Section 13 and 15(d)

November 27, 2024

00000107952024FYFALSEP4YP1YP1Yhttp://www.bd.com/20240930#IntegrationRestructuringAndTransactionExpensehttp://www.bd.com/20240930#IntegrationRestructuringAndTransactionExpensehttp://www.bd.com/20240930#IntegrationRestructuringAndTransactionExpensehttp://fasb.org/us-gaap/2024#AccountsPayableCurrenthttp://fasb.org/us-gaap/2024#AccountsPayableCurrentP1Yhttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent487456456456iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:purebdx:claimbdx:lawsuitbdx:plaintiffbdx:segmentbdx:customeriso4217:EUR00000107952023-10-012024-09-300000010795exch:XNYSus-gaap:CommonStockMember2023-10-012024-09-300000010795exch:XNYSbdx:Notes1.900dueDecember152026Member2023-10-012024-09-300000010795exch:XNYSbdx:Notes3.020dueMay242025Member2023-10-012024-09-300000010795exch:XNYSbdx:Notes1.208dueJune42026Member2023-10-012024-09-300000010795exch:XNYSbdx:Notes1213DueFebruary122036Member2023-10-012024-09-300000010795exch:XNYSbdx:Notes0034DueAugust132025Member2023-10-012024-09-300000010795exch:XNYSbdx:Notes3.519DueFebruary82031Member2023-10-012024-09-300000010795exch:XNYSbdx:Notes3.828DueJune72032Member2023-10-012024-09-3000000107952024-03-3100000107952024-10-3100000107952022-10-012023-09-3000000107952021-10-012022-09-3000000107952024-09-3000000107952023-09-3000000107952022-09-3000000107952021-09-300000010795srt:MinimumMemberus-gaap:BuildingMember2024-09-300000010795srt:MaximumMemberus-gaap:BuildingMember2024-09-300000010795srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-09-300000010795srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-09-300000010795srt:MinimumMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2024-09-300000010795srt:MaximumMemberus-gaap:LeaseholdsAndLeaseholdImprovementsMember2024-09-300000010795bdx:CoreTechnologiesMembersrt:MinimumMember2024-09-300000010795bdx:CoreTechnologiesMembersrt:MaximumMember2024-09-300000010795us-gaap:CustomerRelationshipsMembersrt:MinimumMember2024-09-300000010795us-gaap:CustomerRelationshipsMembersrt:MaximumMember2024-09-300000010795bdx:PatentsAndTrademarksMembersrt:MinimumMember2024-09-300000010795bdx:PatentsAndTrademarksMembersrt:MaximumMember2024-09-300000010795us-gaap:ShippingAndHandlingMember2023-10-012024-09-300000010795us-gaap:ShippingAndHandlingMember2022-10-012023-09-300000010795us-gaap:ShippingAndHandlingMember2021-10-012022-09-300000010795bdx:SurgicalInstrumentationMember2022-10-012023-09-300000010795us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember2022-03-310000010795us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember2021-10-012022-09-300000010795us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember2022-10-012023-09-300000010795us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember2022-04-012022-06-300000010795us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember2021-10-012022-03-310000010795us-gaap:CommonStockMember2021-09-300000010795us-gaap:AdditionalPaidInCapitalMember2021-09-300000010795us-gaap:RetainedEarningsMember2021-09-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2021-09-300000010795us-gaap:TreasuryStockCommonMember2021-09-300000010795us-gaap:RetainedEarningsMember2021-10-012022-09-300000010795us-gaap:AdditionalPaidInCapitalMember2021-10-012022-09-300000010795us-gaap:TreasuryStockCommonMember2021-10-012022-09-300000010795us-gaap:CommonStockMember2022-09-300000010795us-gaap:AdditionalPaidInCapitalMember2022-09-300000010795us-gaap:RetainedEarningsMember2022-09-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2022-09-300000010795us-gaap:TreasuryStockCommonMember2022-09-300000010795us-gaap:RetainedEarningsMember2022-10-012023-09-300000010795us-gaap:CommonStockMember2022-10-012023-09-300000010795us-gaap:AdditionalPaidInCapitalMember2022-10-012023-09-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2022-10-012023-09-300000010795us-gaap:TreasuryStockCommonMember2022-10-012023-09-300000010795us-gaap:CommonStockMember2023-09-300000010795us-gaap:AdditionalPaidInCapitalMember2023-09-300000010795us-gaap:RetainedEarningsMember2023-09-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2023-09-300000010795us-gaap:TreasuryStockCommonMember2023-09-300000010795us-gaap:RetainedEarningsMember2023-10-012024-09-300000010795us-gaap:AdditionalPaidInCapitalMember2023-10-012024-09-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2023-10-012024-09-300000010795us-gaap:TreasuryStockCommonMember2023-10-012024-09-300000010795us-gaap:CommonStockMember2024-09-300000010795us-gaap:AdditionalPaidInCapitalMember2024-09-300000010795us-gaap:RetainedEarningsMember2024-09-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2024-09-300000010795us-gaap:TreasuryStockCommonMember2024-09-300000010795us-gaap:ConvertiblePreferredStockMember2023-06-010000010795us-gaap:CommonStockMember2023-06-010000010795bdx:AcceleratedShareRepurchaseProgramMember2023-10-012024-09-300000010795bdx:AcceleratedShareRepurchaseProgramMember2024-09-300000010795bdx:AcceleratedShareRepurchaseProgramMember2021-10-012022-09-300000010795bdx:AcceleratedShareRepurchaseProgramMember2022-09-300000010795bdx:AcceleratedShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMember2021-10-012022-09-300000010795bdx:AcceleratedShareRepurchaseProgramAgreementOneMember2021-10-012022-09-3000000107952013-09-2400000107952021-11-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-09-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2021-10-012022-09-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-10-012022-09-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-10-012022-09-300000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-10-012022-09-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-09-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2022-10-012023-09-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-10-012023-09-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-10-012023-09-300000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-10-012023-09-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2023-10-012024-09-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-10-012024-09-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-10-012024-09-300000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-10-012024-09-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-09-300000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-300000010795us-gaap:ConvertiblePreferredStockMember2022-10-012023-09-300000010795us-gaap:ConvertiblePreferredStockMember2021-10-012022-09-300000010795bdx:HerniaProductClaimsMember2024-09-300000010795bdx:HerniaProductClaimsMember2023-09-300000010795bdx:SECMatterMember2024-04-012024-06-300000010795bdx:SECMatterMember2024-07-012024-09-300000010795bdx:SECMatterMember2024-09-300000010795stpr:GAsrt:MaximumMember2023-10-012024-09-300000010795stpr:GA2023-10-012024-09-300000010795bdx:ItalianMedicalDevicePaybackLegislationMatterMember2023-10-012024-09-300000010795bdx:PyxisMember2024-09-300000010795us-gaap:OtherOperatingIncomeExpenseMember2023-10-012024-09-300000010795us-gaap:OtherOperatingIncomeExpenseMember2022-10-012023-09-300000010795us-gaap:OtherOperatingIncomeExpenseMember2021-10-012022-09-300000010795bdx:ProductsWithinMassTortLitigationMember2024-09-300000010795bdx:ProductsWithinMassTortLitigationMember2023-09-3000000107952024-10-01bdx:ProductsandorServicesMember2024-09-3000000107952024-10-012024-09-3000000107952024-10-01bdx:ConsumablesMember2024-09-300000010795country:USbdx:MedicationDeliverySolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795us-gaap:NonUsMemberbdx:MedicationDeliverySolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795bdx:MedicationDeliverySolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795country:USbdx:MedicationDeliverySolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795us-gaap:NonUsMemberbdx:MedicationDeliverySolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795bdx:MedicationDeliverySolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795country:USbdx:MedicationDeliverySolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795us-gaap:NonUsMemberbdx:MedicationDeliverySolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795bdx:MedicationDeliverySolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795country:USbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795us-gaap:NonUsMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795bdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795country:USbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795us-gaap:NonUsMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795bdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795country:USbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795us-gaap:NonUsMemberbdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795bdx:MedicationManagementSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795country:USbdx:PharmaceuticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795us-gaap:NonUsMemberbdx:PharmaceuticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795bdx:PharmaceuticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795country:USbdx:PharmaceuticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795us-gaap:NonUsMemberbdx:PharmaceuticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795bdx:PharmaceuticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795country:USbdx:PharmaceuticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795us-gaap:NonUsMemberbdx:PharmaceuticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795bdx:PharmaceuticalSystemsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795country:USbdx:AdvancedPatientMonitoringMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795us-gaap:NonUsMemberbdx:AdvancedPatientMonitoringMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795bdx:AdvancedPatientMonitoringMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795country:USbdx:AdvancedPatientMonitoringMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795us-gaap:NonUsMemberbdx:AdvancedPatientMonitoringMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795bdx:AdvancedPatientMonitoringMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795country:USbdx:AdvancedPatientMonitoringMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795us-gaap:NonUsMemberbdx:AdvancedPatientMonitoringMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795bdx:AdvancedPatientMonitoringMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795us-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012024-09-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795us-gaap:OperatingSegmentsMemberbdx:MedicalMember2022-10-012023-09-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795us-gaap:OperatingSegmentsMemberbdx:MedicalMember2021-10-012022-09-300000010795country:USbdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012024-09-300000010795us-gaap:NonUsMemberbdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012024-09-300000010795bdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012024-09-300000010795country:USbdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2022-10-012023-09-300000010795us-gaap:NonUsMemberbdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2022-10-012023-09-300000010795bdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2022-10-012023-09-300000010795country:USbdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2021-10-012022-09-300000010795us-gaap:NonUsMemberbdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2021-10-012022-09-300000010795bdx:IntegratedDiagnosticSolutionsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2021-10-012022-09-300000010795country:USbdx:BiosciencesMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012024-09-300000010795us-gaap:NonUsMemberbdx:BiosciencesMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012024-09-300000010795bdx:BiosciencesMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012024-09-300000010795country:USbdx:BiosciencesMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2022-10-012023-09-300000010795us-gaap:NonUsMemberbdx:BiosciencesMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2022-10-012023-09-300000010795bdx:BiosciencesMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2022-10-012023-09-300000010795country:USbdx:BiosciencesMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2021-10-012022-09-300000010795us-gaap:NonUsMemberbdx:BiosciencesMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2021-10-012022-09-300000010795bdx:BiosciencesMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2021-10-012022-09-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012024-09-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012024-09-300000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012024-09-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2022-10-012023-09-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2022-10-012023-09-300000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2022-10-012023-09-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2021-10-012022-09-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2021-10-012022-09-300000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2021-10-012022-09-300000010795country:USbdx:SurgeryMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795us-gaap:NonUsMemberbdx:SurgeryMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795bdx:SurgeryMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795country:USbdx:SurgeryMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795us-gaap:NonUsMemberbdx:SurgeryMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795bdx:SurgeryMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795country:USbdx:SurgeryMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795us-gaap:NonUsMemberbdx:SurgeryMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795bdx:SurgeryMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795country:USbdx:PeripheralInterventionMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795us-gaap:NonUsMemberbdx:PeripheralInterventionMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795bdx:PeripheralInterventionMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795country:USbdx:PeripheralInterventionMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795us-gaap:NonUsMemberbdx:PeripheralInterventionMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795bdx:PeripheralInterventionMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795country:USbdx:PeripheralInterventionMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795us-gaap:NonUsMemberbdx:PeripheralInterventionMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795bdx:PeripheralInterventionMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795country:USbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795us-gaap:NonUsMemberbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795bdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795country:USbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795us-gaap:NonUsMemberbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795bdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795country:USbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795us-gaap:NonUsMemberbdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795bdx:UrologyandCriticalCareMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795us-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012024-09-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795us-gaap:OperatingSegmentsMemberbdx:InterventionalMember2022-10-012023-09-300000010795country:USus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795us-gaap:OperatingSegmentsMemberbdx:InterventionalMember2021-10-012022-09-300000010795country:USus-gaap:CorporateNonSegmentMember2023-10-012024-09-300000010795us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2023-10-012024-09-300000010795us-gaap:CorporateNonSegmentMember2023-10-012024-09-300000010795country:USus-gaap:CorporateNonSegmentMember2022-10-012023-09-300000010795us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2022-10-012023-09-300000010795us-gaap:CorporateNonSegmentMember2022-10-012023-09-300000010795country:USus-gaap:CorporateNonSegmentMember2021-10-012022-09-300000010795us-gaap:NonUsMemberus-gaap:CorporateNonSegmentMember2021-10-012022-09-300000010795us-gaap:CorporateNonSegmentMember2021-10-012022-09-300000010795country:US2023-10-012024-09-300000010795us-gaap:NonUsMember2023-10-012024-09-300000010795country:US2022-10-012023-09-300000010795us-gaap:NonUsMember2022-10-012023-09-300000010795country:US2021-10-012022-09-300000010795us-gaap:NonUsMember2021-10-012022-09-300000010795us-gaap:OperatingSegmentsMember2023-10-012024-09-300000010795us-gaap:OperatingSegmentsMember2022-10-012023-09-300000010795us-gaap:OperatingSegmentsMember2021-10-012022-09-300000010795us-gaap:MaterialReconcilingItemsMember2023-10-012024-09-300000010795us-gaap:MaterialReconcilingItemsMember2022-10-012023-09-300000010795us-gaap:MaterialReconcilingItemsMember2021-10-012022-09-300000010795us-gaap:CostOfSalesMemberbdx:MedicalMember2023-10-012024-09-300000010795us-gaap:CostOfSalesMemberbdx:MedicalMember2022-10-012023-09-300000010795us-gaap:CostOfSalesMemberbdx:MedicalMember2021-10-012022-09-300000010795us-gaap:EMEAMember2023-10-012024-09-300000010795us-gaap:EMEAMember2022-10-012023-09-300000010795us-gaap:EMEAMember2021-10-012022-09-300000010795srt:AsiaMember2023-10-012024-09-300000010795srt:AsiaMember2022-10-012023-09-300000010795srt:AsiaMember2021-10-012022-09-300000010795bdx:OthersCountryMember2023-10-012024-09-300000010795bdx:OthersCountryMember2022-10-012023-09-300000010795bdx:OthersCountryMember2021-10-012022-09-300000010795country:US2024-09-300000010795country:US2023-09-300000010795country:US2022-09-300000010795us-gaap:EMEAMember2024-09-300000010795us-gaap:EMEAMember2023-09-300000010795us-gaap:EMEAMember2022-09-300000010795srt:AsiaMember2024-09-300000010795srt:AsiaMember2023-09-300000010795srt:AsiaMember2022-09-300000010795bdx:OthersCountryMember2024-09-300000010795bdx:OthersCountryMember2023-09-300000010795bdx:OthersCountryMember2022-09-300000010795us-gaap:CorporateMember2024-09-300000010795us-gaap:CorporateMember2023-09-300000010795us-gaap:CorporateMember2022-09-300000010795us-gaap:CostOfSalesMember2023-10-012024-09-300000010795us-gaap:CostOfSalesMember2022-10-012023-09-300000010795us-gaap:CostOfSalesMember2021-10-012022-09-300000010795us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-10-012024-09-300000010795us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-10-012023-09-300000010795us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-10-012022-09-300000010795us-gaap:ResearchAndDevelopmentExpenseMember2023-10-012024-09-300000010795us-gaap:ResearchAndDevelopmentExpenseMember2022-10-012023-09-300000010795us-gaap:ResearchAndDevelopmentExpenseMember2021-10-012022-09-300000010795bdx:AcquisitionRelatedCostsAndRestructuringChargesMember2023-10-012024-09-300000010795bdx:AcquisitionRelatedCostsAndRestructuringChargesMember2022-10-012023-09-300000010795bdx:AcquisitionRelatedCostsAndRestructuringChargesMember2021-10-012022-09-300000010795us-gaap:StockAppreciationRightsSARSMember2023-10-012024-09-300000010795us-gaap:StockAppreciationRightsSARSMember2022-10-012023-09-300000010795us-gaap:StockAppreciationRightsSARSMember2021-10-012022-09-300000010795bdx:RestrictedStockUnitsPerformancePsuMember2023-10-012024-09-300000010795bdx:RestrictedStockUnitsPerformancePsuMembersrt:MinimumMember2023-10-012024-09-300000010795bdx:RestrictedStockUnitsPerformancePsuMembersrt:MaximumMember2023-10-012024-09-300000010795us-gaap:RestrictedStockUnitsRSUMember2023-10-012024-09-300000010795us-gaap:RestrictedStockUnitsRSUMembersrt:ExecutiveOfficerMember2023-10-012024-09-300000010795bdx:RestrictedStockUnitsPerformancePsuMember2023-09-300000010795us-gaap:RestrictedStockUnitsRSUMember2023-09-300000010795bdx:RestrictedStockUnitsPerformancePsuMember2024-09-300000010795us-gaap:RestrictedStockUnitsRSUMember2024-09-300000010795bdx:RestrictedStockUnitsPerformancePsuMember2022-10-012023-09-300000010795bdx:RestrictedStockUnitsPerformancePsuMember2021-10-012022-09-300000010795us-gaap:RestrictedStockUnitsRSUMember2022-10-012023-09-300000010795us-gaap:RestrictedStockUnitsRSUMember2021-10-012022-09-300000010795srt:DirectorMember2024-09-300000010795us-gaap:PensionPlansDefinedBenefitMember2023-10-012024-09-300000010795us-gaap:PensionPlansDefinedBenefitMember2022-10-012023-09-300000010795us-gaap:PensionPlansDefinedBenefitMember2021-10-012022-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-10-012024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-10-012023-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2021-10-012022-09-300000010795us-gaap:PensionPlansDefinedBenefitMember2023-09-300000010795us-gaap:PensionPlansDefinedBenefitMember2022-09-300000010795us-gaap:PensionPlansDefinedBenefitMember2024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-09-300000010795country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-09-300000010795country:USus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMember2023-10-012024-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMember2022-10-012023-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMember2021-10-012022-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMember2024-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMember2023-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMember2022-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2022-09-300000010795us-gaap:FixedIncomeFundsMember2024-09-300000010795bdx:DiversifiedMember2024-09-300000010795us-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2024-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2023-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2024-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2023-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2024-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2023-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2024-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2023-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2024-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2023-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2024-09-300000010795country:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2023-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2024-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2023-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2024-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2023-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2024-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2023-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2024-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2023-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMember2024-09-300000010795country:USbdx:InvestmentsMeasuredAtNetAssetValuePerShareMemberus-gaap:PensionPlansDefinedBenefitMember2023-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-09-300000010795us-gaap:FairValueInputsLevel1Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-09-300000010795us-gaap:FairValueInputsLevel2Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2024-09-300000010795us-gaap:FairValueInputsLevel3Membercountry:USus-gaap:PensionPlansDefinedBenefitMember2023-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2023-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2023-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2024-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2023-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2024-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2023-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2024-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherFixedIncomeMember2023-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2024-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesMember2023-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2024-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CashAndCashEquivalentsMember2023-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2024-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2023-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:InsuranceContractInvestmentsMember2024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:InsuranceContractInvestmentsMember2023-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:InsuranceContractInvestmentsMember2024-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:InsuranceContractInvestmentsMember2023-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:InsuranceContractInvestmentsMember2024-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:InsuranceContractInvestmentsMember2023-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:InsuranceContractInvestmentsMember2024-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:InsuranceContractInvestmentsMember2023-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2024-09-300000010795us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2023-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2024-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2023-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2024-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2023-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2024-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMemberbdx:OtherPensionPlanInvestmentsMember2023-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-09-300000010795us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-09-300000010795us-gaap:FairValueInputsLevel2Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-09-300000010795us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-09-300000010795bdx:AdvancedPatientMonitoringMember2024-09-032024-09-030000010795bdx:AdvancedPatientMonitoringMemberus-gaap:DevelopedTechnologyRightsMember2024-09-030000010795bdx:AdvancedPatientMonitoringMemberus-gaap:CustomerRelationshipsMember2024-09-030000010795bdx:AdvancedPatientMonitoringMember2024-09-030000010795bdx:AdvancedPatientMonitoringMember2024-09-300000010795bdx:AdvancedPatientMonitoringMember2023-10-012024-09-300000010795bdx:AdvancedPatientMonitoringMember2022-10-012023-09-300000010795bdx:ParataSystemsMember2022-07-182022-07-180000010795bdx:ParataSystemsMemberus-gaap:DevelopedTechnologyRightsMember2022-07-180000010795bdx:ParataSystemsMemberus-gaap:CustomerRelationshipsMember2022-07-180000010795bdx:ParataSystemsMember2022-07-180000010795us-gaap:EmployeeSeveranceMember2021-09-300000010795us-gaap:OtherRestructuringMember2021-09-300000010795us-gaap:EmployeeSeveranceMember2021-10-012022-09-300000010795us-gaap:OtherRestructuringMember2021-10-012022-09-300000010795us-gaap:EmployeeSeveranceMember2022-09-300000010795us-gaap:OtherRestructuringMember2022-09-300000010795us-gaap:EmployeeSeveranceMember2022-10-012023-09-300000010795us-gaap:OtherRestructuringMember2022-10-012023-09-300000010795us-gaap:EmployeeSeveranceMember2023-09-300000010795us-gaap:OtherRestructuringMember2023-09-300000010795us-gaap:EmployeeSeveranceMember2023-10-012024-09-300000010795us-gaap:OtherRestructuringMember2023-10-012024-09-300000010795us-gaap:EmployeeSeveranceMember2024-09-300000010795us-gaap:OtherRestructuringMember2024-09-300000010795us-gaap:DevelopedTechnologyRightsMember2024-09-300000010795us-gaap:DevelopedTechnologyRightsMember2023-09-300000010795us-gaap:CustomerRelationshipsMember2024-09-300000010795us-gaap:CustomerRelationshipsMember2023-09-300000010795us-gaap:IntellectualPropertyMember2024-09-300000010795us-gaap:IntellectualPropertyMember2023-09-300000010795us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember2024-09-300000010795us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember2023-09-300000010795us-gaap:TrademarksMember2024-09-300000010795us-gaap:TrademarksMember2023-09-300000010795bdx:MedicalMember2022-09-300000010795bdx:LifeSciencesMember2022-09-300000010795bdx:InterventionalMember2022-09-300000010795bdx:MedicalMember2022-10-012023-09-300000010795bdx:LifeSciencesMember2022-10-012023-09-300000010795bdx:InterventionalMember2022-10-012023-09-300000010795bdx:MedicalMember2023-09-300000010795bdx:LifeSciencesMember2023-09-300000010795bdx:InterventionalMember2023-09-300000010795bdx:MedicalMember2023-10-012024-09-300000010795bdx:LifeSciencesMember2023-10-012024-09-300000010795bdx:InterventionalMember2023-10-012024-09-300000010795bdx:MedicalMember2024-09-300000010795bdx:LifeSciencesMember2024-09-300000010795bdx:InterventionalMember2024-09-300000010795us-gaap:ForeignExchangeContractMember2024-09-300000010795us-gaap:ForeignExchangeContractMember2023-09-300000010795us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-09-300000010795us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-09-300000010795us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMember2024-09-300000010795us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMember2023-09-300000010795us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-09-300000010795us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2023-09-300000010795us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-10-012024-09-300000010795us-gaap:ForeignExchangeContractMember2023-10-012024-09-300000010795us-gaap:ForeignExchangeContractMember2022-10-012023-09-300000010795us-gaap:ForeignExchangeContractMember2021-10-012022-09-300000010795us-gaap:CurrencySwapMember2023-10-012024-09-300000010795us-gaap:CurrencySwapMember2022-10-012023-09-300000010795us-gaap:CurrencySwapMember2021-10-012022-09-300000010795bdx:TerminatedCurrencySwapMember2023-10-012024-09-300000010795bdx:TerminatedCurrencySwapMember2022-10-012023-09-300000010795bdx:TerminatedCurrencySwapMember2021-10-012022-09-300000010795us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-10-012024-09-300000010795us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2022-10-012023-09-300000010795us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2021-10-012022-09-300000010795bdx:FixedToFloatingMemberus-gaap:FairValueHedgingMember2024-09-300000010795bdx:FixedToFloatingMemberus-gaap:FairValueHedgingMember2023-09-300000010795us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2024-09-300000010795us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2023-09-300000010795srt:MinimumMember2023-10-012024-09-300000010795srt:MaximumMember2023-10-012024-09-300000010795bdx:IntegrationRestructuringAndTransactionExpenseMember2023-10-012024-09-300000010795us-gaap:CostOfSalesMemberbdx:LifeSciencesMember2021-10-012022-09-300000010795bdx:AcquisitionRelatedCostsAndRestructuringChargesMemberbdx:MedicalMember2021-10-012022-09-300000010795srt:MinimumMember2024-09-300000010795srt:MaximumMember2024-09-300000010795us-gaap:CommercialPaperMember2024-09-300000010795us-gaap:CommercialPaperMember2023-09-300000010795bdx:Notes3875DueMay152024Member2024-09-300000010795bdx:Notes3875DueMay152024Member2023-09-300000010795bdx:Notes3.363DueJune62024Member2024-09-300000010795bdx:Notes3.363DueJune62024Member2023-09-300000010795bdx:Notes3.734DueDecember152024Member2024-09-300000010795bdx:Notes3.734DueDecember152024Member2023-09-300000010795bdx:Notes3.020dueMay242025Member2024-09-300000010795bdx:Notes3.020dueMay242025Member2023-09-300000010795bdx:Notes0034DueAugust132025Member2024-09-300000010795bdx:Notes0034DueAugust132025Member2023-09-300000010795bdx:Notes1.208dueJune42026Member2024-09-300000010795bdx:Notes1.208dueJune42026Member2023-09-300000010795bdx:Notes6.700dueDecember12026Member2024-09-300000010795bdx:Notes6.700dueDecember12026Member2023-09-300000010795bdx:Notes1.900dueDecember152026Member2024-09-300000010795bdx:Notes1.900dueDecember152026Member2023-09-300000010795bdx:Notes3.700dueJune62027Member2024-09-300000010795bdx:Notes3.700dueJune62027Member2023-09-300000010795bdx:DebenturesDue2027Member2024-09-300000010795bdx:DebenturesDue2027Member2023-09-300000010795bdx:Notes4693DueFebruary132028Member2024-09-300000010795bdx:Notes4693DueFebruary132028Member2023-09-300000010795bdx:DebenturesDue2028Member2024-09-300000010795bdx:DebenturesDue2028Member2023-09-300000010795bdx:Notes0334DueAugust132028Member2024-09-300000010795bdx:Notes0334DueAugust132028Member2023-09-300000010795bdx:Notes4.874DueFebruary82029Member2024-09-300000010795bdx:Notes4.874DueFebruary82029Member2023-09-300000010795bdx:Notes5.081DueJune72029Member2024-09-300000010795bdx:Notes5.081DueJune72029Member2023-09-300000010795bdx:Notes3553DueSeptember132029Member2024-09-300000010795bdx:Notes3553DueSeptember132029Member2023-09-300000010795bdx:Notes2823DueMay202030Member2024-09-300000010795bdx:Notes2823DueMay202030Member2023-09-300000010795bdx:Notes3.519DueFebruary82031Member2024-09-300000010795bdx:Notes3.519DueFebruary82031Member2023-09-300000010795bdx:Notes1957DueFebruary112031Member2024-09-300000010795bdx:Notes1957DueFebruary112031Member2023-09-300000010795bdx:Notes3.828DueJune72032Member2024-09-300000010795bdx:Notes3.828DueJune72032Member2023-09-300000010795bdx:Notes4298DueAugust222032Member2024-09-300000010795bdx:Notes4298DueAugust222032Member2023-09-300000010795bdx:Notes5.110DueFebruary82034Member2024-09-300000010795bdx:Notes5.110DueFebruary82034Member2023-09-300000010795bdx:Notes1213DueFebruary122036Member2024-09-300000010795bdx:Notes1213DueFebruary122036Member2023-09-300000010795bdx:Notes4.029DueJune72036Member2024-09-300000010795bdx:Notes4.029DueJune72036Member2023-09-300000010795bdx:NotesDue2039Member2024-09-300000010795bdx:NotesDue2039Member2023-09-300000010795bdx:NotesDue2040Member2024-09-300000010795bdx:NotesDue2040Member2023-09-300000010795bdx:Notes1336DueAugust132041Member2024-09-300000010795bdx:Notes1336DueAugust132041Member2023-09-300000010795bdx:Notes4.875dueMay152044Member2024-09-300000010795bdx:Notes4.875dueMay152044Member2023-09-300000010795bdx:Notes4.685dueDecember152044Member2024-09-300000010795bdx:Notes4.685dueDecember152044Member2023-09-300000010795bdx:Notes4.669DueJune62047Member2024-09-300000010795bdx:Notes4.669DueJune62047Member2023-09-300000010795bdx:Notes3794DueMay202050Member2024-09-300000010795bdx:Notes3794DueMay202050Member2023-09-300000010795bdx:OtherLongtermDebtMember2024-09-300000010795bdx:OtherLongtermDebtMember2023-09-300000010795us-gaap:RevolvingCreditFacilityMember2024-07-012024-07-310000010795srt:MaximumMemberus-gaap:RevolvingCreditFacilityMember2024-09-300000010795us-gaap:RevolvingCreditFacilityMember2024-09-300000010795us-gaap:RevolvingCreditFacilityMember2023-09-300000010795bdx:Notes1.401dueMay242023Member2024-09-300000010795bdx:Notes0000DueAugust132023Member2024-09-300000010795currency:EURbdx:Notes3.828DueJune72032Member2024-09-300000010795currency:USDbdx:Notes3.828DueJune72032Member2024-09-300000010795currency:EURbdx:Notes3.519DueFebruary82031Member2024-09-300000010795currency:USDbdx:Notes3.519DueFebruary82031Member2024-09-300000010795currency:EURbdx:Notes4.029DueJune72036Member2024-09-300000010795currency:USDbdx:Notes4.029DueJune72036Member2024-09-300000010795currency:EURbdx:Notes3553DueSeptember132029Member2023-09-300000010795currency:USDbdx:Notes3553DueSeptember132029Member2023-09-300000010795bdx:Notes0.632dueJune42023Member2024-09-300000010795currency:EURbdx:Notes0000DueAugust132023Member2024-09-300000010795currency:USDbdx:Notes0000DueAugust132023Member2024-09-300000010795currency:EURbdx:Notes0.632dueJune42023Member2024-09-300000010795currency:USDbdx:Notes0.632dueJune42023Member2024-09-300000010795currency:EURbdx:Notes1.401dueMay242023Member2024-09-300000010795currency:USDbdx:Notes1.401dueMay242023Member2024-09-300000010795currency:EURbdx:Notes1.000dueDecember152022Member2024-09-300000010795currency:USDbdx:Notes1.000dueDecember152022Member2024-09-300000010795bdx:Notes1.000dueDecember152022Member2024-09-300000010795us-gaap:AllowanceForCreditLossMember2021-09-300000010795bdx:ReserveforCashDiscountsMember2021-09-300000010795us-gaap:AllowanceForCreditLossMember2021-10-012022-09-300000010795bdx:ReserveforCashDiscountsMember2021-10-012022-09-300000010795us-gaap:AllowanceForCreditLossMember2022-09-300000010795bdx:ReserveforCashDiscountsMember2022-09-300000010795us-gaap:AllowanceForCreditLossMember2022-10-012023-09-300000010795bdx:ReserveforCashDiscountsMember2022-10-012023-09-300000010795us-gaap:AllowanceForCreditLossMember2023-09-300000010795bdx:ReserveforCashDiscountsMember2023-09-300000010795us-gaap:AllowanceForCreditLossMember2023-10-012024-09-300000010795bdx:ReserveforCashDiscountsMember2023-10-012024-09-300000010795us-gaap:AllowanceForCreditLossMember2024-09-300000010795bdx:ReserveforCashDiscountsMember2024-09-300000010795bdx:MichaelGarrisonMember2024-07-012024-09-300000010795bdx:MichaelGarrisonTradingArrangementStockAppreciationRightsMemberbdx:MichaelGarrisonMember2024-09-300000010795bdx:MichaelGarrisonTradingArrangementCommonStockMemberbdx:MichaelGarrisonMember2024-09-300000010795bdx:MichaelGarrisonTradingArrangementCommonStockUponTheVestingOfTimeVestedUnitsMemberbdx:MichaelGarrisonMember2024-09-300000010795bdx:MichaelGarrisonTradingArrangementCommonStockUponTheVestingOfPerformanceUnitsMemberbdx:MichaelGarrisonMember2024-09-300000010795bdx:DavidShanMember2024-07-012024-09-300000010795bdx:DavidShanTradingArrangementCommonStockMemberbdx:DavidShanMember2024-09-300000010795bdx:DavidShanTradingArrangementCommonStockUponTheVestingOfTimeVestedUnitsMemberbdx:DavidShanMember2024-09-300000010795bdx:ShanaNealMember2024-07-012024-09-300000010795bdx:ShanaNealMember2024-09-300000010795bdx:RolandGoetteMember2024-07-012024-09-300000010795bdx:RolandGoetteTradingArrangementStockAppreciationRightsMemberbdx:RolandGoetteMember2024-09-300000010795bdx:RolandGoetteTradingArrangementCommonStockMemberbdx:RolandGoetteMember2024-09-3000000107952024-07-012024-09-300000010795bdx:OfficerTradingArrangementMemberbdx:MichaelGarrisonMember2023-10-012024-09-300000010795bdx:OfficerTradingArrangementMemberbdx:DavidShanMember2023-10-012024-09-300000010795bdx:OfficerTradingArrangementMemberbdx:ShanaNealMember2023-10-012024-09-300000010795bdx:OfficerTradingArrangementMemberbdx:RolandGoetteMember2023-10-012024-09-30
Table of Contents
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
(Mark One)
    ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended September 30, 2024
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
COMMISSION FILE NUMBER: 001-4802
BECTON, DICKINSON AND COMPANY
(Exact name of registrant as specified in its charter)
New Jersey    22-0760120
(State or other jurisdiction of incorporation or organization)    (I.R.S. Employer Identification No.)
1 Becton Drive, Franklin Lakes, New Jersey 07417-1880
(Address of principal executive offices) (Zip code)
Registrant’s telephone number, including area code (201) 847-6800
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
Common stock, par value $1.00 BDX New York Stock Exchange
1.900% Notes due December 15, 2026 BDX26 New York Stock Exchange
3.020% Notes due May 24, 2025 BDX25 New York Stock Exchange
1.208% Notes due June 4, 2026 BDX/26A New York Stock Exchange
1.213% Notes due February 12, 2036 BDX/36 New York Stock Exchange
0.034% Notes due August 13, 2025 BDX25A New York Stock Exchange
3.519% Notes due February 8, 2031 BDX31 New York Stock Exchange
3.828% Notes due June 7, 2032 BDX32A New York Stock Exchange
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☑        No  ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐        No  ☑
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☑        No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☑        No  ☐
Indicate by check mark whether the registrant is a "large accelerated filer," an "accelerated filer," a "non-accelerated filer," a "smaller reporting company," or an "emerging growth company."
Large accelerated filer  
   Accelerated filer  
Non-accelerated filer  
Smaller reporting company  
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.          
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).  ☐        
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes          No  ☑
As of March 31, 2024, the aggregate market value of the registrant’s outstanding common stock held by non-affiliates of the registrant was approximately $71,455,056,628.
As of October 31, 2024, 289,122,120 shares of the registrant’s common stock were outstanding.
Documents Incorporated by Reference. Portions of the registrant’s Proxy Statement for the Annual Meeting of Shareholders to be held January 28, 2025 are incorporated by reference into Part III hereof.


Table of Contents
TABLE OF CONTENTS


Table of Contents
PART I
Item  1.    Business.
General
Becton, Dickinson and Company (also referred to herein as "BD") was incorporated under the laws of the State of New Jersey in November 1906, as successor to a New York business started in 1897. BD’s executive offices are located at 1 Becton Drive, Franklin Lakes, New Jersey 07417-1880, and its telephone number is (201) 847-6800. All references in this Form 10-K to "BD", "the Company", "we", "our" or "us" refer to Becton, Dickinson and Company and its domestic and foreign subsidiaries, unless otherwise indicated by the context.
BD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. We provide customer solutions that are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology care; enhancing the diagnosis of infectious diseases and cancers; and advancing cellular research and applications.
Business Segments
BD’s operations consist of three worldwide business segments: BD Medical, BD Life Sciences and BD Interventional. As is further described below, on September 3, 2024, BD completed its acquisition of Edwards Lifesciences’ Critical Care product group (“Critical Care”), which was renamed as BD Advanced Patient Monitoring (“Advanced Patient Monitoring”) and operates as a separate organizational unit within the Company’s Medical segment. Information with respect to BD’s business segments is included in Notes 8, 11 and 16, respectively, to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, and is incorporated herein by reference.
BD Medical
BD Medical produces a broad array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The primary customers served by BD Medical are hospitals and clinics; physicians’ office practices; consumers and retail pharmacies; governmental and nonprofit public health agencies; pharmaceutical companies; and healthcare workers. BD Medical consists of the following organizational units:
1

Table of Contents
Organizational Unit
Principal Product Lines
Medication Delivery
Solutions
Peripheral intravenous ("IV") catheters (conventional, safety); advanced peripheral catheters (guidewire assisted peripherally inserted venous catheters, midline catheters, port access); central lines (peripherally inserted central catheters); acute dialysis catheters; vascular access technology (ultrasonic imaging); vascular care (lock solutions, prefilled flush syringes, disinfecting caps); vascular preparation (skin antiseptics, dressings, securement); needle-free IV connectors and extensions sets; closed-system drug transfer devices; hazardous drug detection; conventional and safety hypodermic syringes and needles, anesthesia needles (spinal, epidural) and trays; enteral syringes; and sharps disposal systems.
Medication Management
Solutions
IV medication safety and infusion therapy delivery systems, including infusion pumps, dedicated disposables, and IV fluids; medication compounding workflow systems; automated medication dispensing; automated supply management systems; medication inventory optimization and tracking systems; informatics and analytics solutions for enterprise medication management; and pharmacy automation systems.
Pharmaceutical
Systems
Prefillable drug delivery systems - prefillable syringes, safety, shielding and self-injection systems and support services (combination product testing, technical and regulatory) - provided to pharmaceutical companies for use as containers for injectable pharmaceutical products, which are then placed on the market as drug/device combinations.
Advanced Patient Monitoring Advanced hemodynamic monitoring systems used to measure a patient's heart function and fluid status in surgical and intensive care settings.

BD Life Sciences
BD Life Sciences provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. In addition, BD Life Sciences produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. That information is used to aid the discovery and development of new drugs and vaccines, and to improve the diagnosis and management of diseases. The primary customers served by BD Life Sciences are hospitals, laboratories and clinics; blood banks; healthcare workers; physicians’ office practices; academic and government institutions; and pharmaceutical and biotechnology companies. BD Life Sciences consists of the following organizational units:
Organizational Unit Principal Product Lines
Integrated Diagnostic Solutions
Integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women’s health; microorganism identification and drug susceptibility systems; liquid-based cytology systems and HPV tests for cervical cancer screening and genotyping; rapid diagnostic assays for testing of respiratory infections at the point of care; microbiology laboratory automation; and plated media for clinical and industrial applications.
Biosciences
Fluorescence-activated cell sorters and analyzers; antibodies and kits for performing cell analysis; reagents for life science research; solutions for high-throughput single-cell gene and protein expression analysis; and clinical oncology, immunological (HIV) and transplantation diagnostic/monitoring reagents, analyzers and informatics.


2

Table of Contents
BD Interventional
BD Interventional provides vascular, urology, oncology and surgical specialty products that are intended to be used once and then discarded or are either temporarily or permanently implanted. The primary customers served by BD Interventional are hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via our Homecare business. BD Interventional consists of the following organizational units:

Organizational Unit Principal Product Lines
Surgery Hernia and soft tissue repair, biological grafts, bioresorbable grafts, biosurgery, and other surgical products, BD Surgiphor™ Antimicrobial Irrigation System, and BD ChloraPrep™ surgical infection prevention products.
Peripheral Intervention
Percutaneous transluminal angioplasty (“PTA”) balloon catheters, radio frequency ablation catheters, peripheral vascular stents, self-expanding and balloon-expandable stent grafts, vascular grafts, drug coated balloons, ports, biopsy, chronic dialysis, inferior vena catheter filters, endovascular fistula creation devices and drainage products, and atherectomy and thrombectomy systems.
Urology and Critical Care Urine management and measurement devices, indwelling, intermittent and external urine catheters, kidney stone management devices, Targeted Temperature Management, and fecal management devices.

Acquisitions
Edwards Lifesciences’ Critical Care Product Group
On September 3, 2024, BD completed the acquisition of Critical Care, which was renamed as BD Advanced Patient Monitoring. The fair value of consideration transferred in connection with the acquisition was $3.911 billion. Since the acquisition date, financial results for Advanced Patient Monitoring’s product offerings are being reported as a separate organizational unit within the Medical segment. BD funded the transaction with cash on hand, using net proceeds raised through debt issuances in the third quarter of fiscal year 2024, as further discussed in Note 16, and borrowings under our commercial paper program. Additional information regarding this acquisition is contained in Note 11 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, which is incorporated herein by reference.
Parata
On July 18, 2022, BD completed the acquisition of Parata Systems (“Parata”), an innovative provider of pharmacy automation solutions. The fair value of consideration transferred in connection with the acquisition was $1.548 billion. Since the acquisition date, financial results for Parata's product offerings are being reported within results for the Medical segment’s Medication Management Solutions unit. Additional information regarding this acquisition is contained in Note 11 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, which is incorporated herein by reference.





3

Table of Contents
Divestitures
Surgical Instrumentation Platform
In August 2023, BD completed the sale of the Interventional segment’s Surgical Instrumentation platform pursuant to a definitive agreement that was signed in June 2023. BD recognized a pre-tax gain on the sale of approximately $268 million, which was recorded as a component of Other operating expense (income), net in fiscal year 2023. The historical financial results for the Surgical Instrumentation platform have not been classified as a discontinued operation. Additional information regarding this divestiture is contained in Note 2 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, which is incorporated herein by reference.
Spin-Off of Diabetes Care
On April 1, 2022, BD completed the separation and distribution of Embecta Corp. (“Embecta”), formerly BD's Diabetes Care business, into a separate, publicly-traded company. The historical results of the Diabetes Care business (previously included in BD’s Medical segment), as well as interest expense related to indebtedness incurred by Embecta prior to the spin-off date, have been reflected as discontinued operations in our consolidated financial statements for all periods prior to the spin-off date of April 1, 2022. Additional disclosures regarding our spin-off of the Diabetes Care business are provided in Note 2 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, which is incorporated herein by reference.
International Operations
BD’s products are manufactured and sold worldwide. For reporting purposes, we organize our operations outside the United States as follows: EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, and Australia and New Zealand); Latin America (which includes Mexico, Central America, the Caribbean and South America); and Canada. BD has manufacturing operations outside the United States in Bosnia and Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, the Netherlands, Singapore, Spain, and the United Kingdom. Geographic information with respect to BD’s operations is included under the heading “Geographic Information” in Note 8 to the consolidated financial statements included in Item 8. Financial Statements and Supplementary Data.
Foreign economic conditions and exchange rate fluctuations have caused the profitability related to foreign revenues to fluctuate more than the profitability related to domestic revenues. BD believes its activities in some countries outside the United States involve greater risk than its domestic business due to the factors cited herein. See further discussion of these risks in Item 1A. Risk Factors.
Distribution
BD’s products are marketed and distributed in the United States and internationally through independent distribution channels, as well as directly to hospitals and other healthcare related institutions by BD and independent sales representatives. BD uses acute care, non-acute care, laboratory and drug wholesaler distributors to broadly support our overall disposable product demand from our end user customers in the United States, while our capital equipment is mostly sold direct to our end user customers. In international markets, products are distributed either directly or through distributors, with the practice varying by country. BD’s worldwide sales are not generally seasonal, with the exception of certain medical devices in the Medication Delivery Solutions business unit, and flu diagnostic products in the Integrated Diagnostic Systems business unit, both of which relate to seasonal diseases such as influenza. BD operates consolidated distribution facilities globally in order to better service its customers, optimize logistics, lower facilities costs and reduce finished goods inventory levels.

4

Table of Contents

Raw Materials and Components
BD purchases many different types of raw materials and components, including plastics, glass, metals, textiles, paper products, agricultural products, electronic and mechanical sub-assemblies and various biological, chemical and petrochemical products. BD seeks to ensure continuity of supply by securing multiple options for sourcing. However, there are situations where raw materials and components are only available from one supplier, which are referred to as sole sourced. The use of sole sourced materials and components may be due to sourcing of proprietary and/or patented technology and processes that are intended to provide a unique market differentiation to our product. In other cases, while a raw material or component can be sourced from multiple manufacturers, only one supplier is qualified due to quality assurance, cost or other considerations. In order to provide alternate sources, BD must complete a rigorous qualification process, which most often includes completion of regulatory registration and approval. If clinical trials are not required, this qualification process can take 3-18 months depending on the criticality of the change. When clinical trials are required, this process may lengthen the qualification phase from one to three years. BD continuously assesses its sole sourced raw materials and components, and maintains business continuity plans with its suppliers. BD’s continuity plans may include securing secondary supply with alternate suppliers, qualification of alternate manufacturing facilities, maintaining contingency stock, internal development of supply and establishment of technology escrow accounts. While BD works closely with its suppliers, no assurance can be given that these efforts will be successful, and there may be events that cause supply interruption, reduction or termination that adversely impact BD’s ability to manufacture and sell certain products. See further discussion of the risks related to the supply chain and raw materials in Item 1A. Risk Factors.
Research and Development
BD conducts its research and development (“R&D”) activities at its operating units and across global enterprise centers of excellence located in the United States, India, China, Singapore and Ireland. The majority of BD’s R&D activities are conducted in North America. Outside North America, BD has a significant R&D presence in Greater Asia and Europe. BD also collaborates with certain universities, medical centers and other entities on R&D programs and retains individual consultants and partners to support its efforts in specialized fields. 
Intellectual Property and Licenses
BD owns significant intellectual property, including patents, patent applications, technology, trade secrets, know-how, copyrights and trademarks in the United States and other countries. BD is also licensed under domestic and foreign patents, patent applications, technology, trade secrets, know-how, copyrights and trademarks owned by others. In the aggregate, these intellectual property assets and licenses are of material importance to BD’s business. BD believes, however, that no single patent, technology, trademark, intellectual property asset or license is material in relation to BD’s business as a whole, or to any business segment.
Competition
BD operates in the increasingly complex and challenging medical technology marketplace. Technological advances and scientific discoveries have accelerated the pace of change in medical technology, the regulatory environment of medical products is becoming more complex and vigorous, and economic conditions have resulted in a challenging market. Companies of varying sizes compete in the global medical technology field. Some are more specialized than BD with respect to particular markets, and some have greater financial resources than BD. New companies have entered the field, particularly in the areas of molecular diagnostics, non-traditional point of care and at-home testing, safety-engineered devices and in the life sciences. Additionally, established companies have diversified their business activities into the medical technology area. Other firms engaged in the distribution of medical technology products have become manufacturers of medical devices and instruments as well. Acquisitions and collaborations by and among companies seeking a competitive advantage also affect the competitive environment. In addition, the entry into the market of low-
5

Table of Contents
cost manufacturers has created increased pricing pressures. BD competes in this evolving marketplace on the basis of many factors, including price, quality, innovation, service, reputation, distribution and promotion. The impact of these factors on BD’s competitive position varies among BD’s various product offerings. In order to remain competitive in the industries in which it operates and to boost supply reliability and productivity, BD continues to make investments in R&D, quality management, quality improvement, product innovation, manufacturing and supply chain. See further discussion of the risks relating to competition in the medical technology industry in Item 1A. Risk Factors.
Market Access and Third-Party Reimbursement
BD’s customers and their patients rely on public and private payers to reimburse some or all the cost of procedures, products and services. BD actively engages with the payer community, medical societies and other stakeholders in order to navigate market access trends and appropriately communicate value propositions for a broad range of BD medical technologies. However, BD has no direct control over payer decision-making with respect to coverage and payment levels for BD products.
The manner and level of reimbursement is determined at the payer’s discretion and may depend on a variety of factors, including but not limited to site of care, procedure(s) performed, patient diagnosis, the device(s) and/or drug(s) utilized, available budget, health equity, beneficiary access or a combination of these factors. The providers that we serve are also evaluating changes in the healthcare reimbursement landscape and coverage elements leading to their own decision-making on what they will ultimately pay for various medical technologies or procedures, which could positively or negatively impact sales of BD products in any given country for any given product at any given time.
Vertical integration of health systems has created a concentrated market among commercial payers in the U.S. and there is an increased focus globally on payment policies that serve to control healthcare spending while also rewarding quality and patient outcomes. Governments around the world continue to consider and transition to value-based payment reforms that would drive improved value and quality- and resource-based reimbursement. For example, the Centers for Medicare & Medicaid Services’ (CMS) established a 2030 goal of transitioning all Medicare fee-for-service beneficiaries to a “care relationship” to ensure the agency’s accountability of quality and cost of care. Whether these changes are driven by legislative efforts, strategic alliances or market conditions, the global landscape continues to enhance cost control efforts through “pay for performance” mechanisms and bidding and tender policies that focus on quality and performance.
Examining reimbursement and continually assessing the broader healthcare funding landscape is a strategic consideration in the development and marketing of medical technology. Advancing coding, coverage and payment strategies reduce barriers to adoption, improve affordability and are critical to ensuring patient and provider access to medical technologies. Market access strategies are also critical in ensuring commercial priorities are meeting the demand for critical healthcare needs globally and locally.
Regulation
General
BD's operations are global and are affected by complex state, federal and international laws relating to healthcare, environmental protection, occupational health and safety, antitrust, anti-corruption, marketing, fraud and abuse (including anti-kickback and false claims laws), export control, product safety and efficacy, employment, privacy and other areas.
BD’s medical technology products and operations are subject to regulation by the U.S. Food and Drug Administration (“FDA”) and various other federal and state agencies, as well as by foreign governmental agencies. These agencies enforce laws and regulations that govern the development, testing, manufacturing, labeling, advertising, marketing and distribution, and market surveillance of BD’s medical products. The scope of the activities of these agencies, particularly in the Europe, Japan, Latin America, and Asia Pacific regions in which BD operates, has been increasing.
6

Table of Contents
In order to market or sell most of its products, BD must secure authorization from the FDA and counterpart foreign regulatory agencies. After a device has received 510(k) clearance, premarket (PMA) approval or other marketing authorization for a specific intended use, any change or modification that significantly affects its safety or effectiveness, such as a significant change or changes in the design, materials, method of manufacture or intended use, may require a new marketing authorization. The determination as to whether or not a modification or series of modifications could significantly affect the device’s safety or effectiveness is initially left to the manufacturer to assess using available guidance; however, regulators may review this determination to evaluate the regulatory status of the modified product at any time and may require the manufacturer to cease marketing and recall the modified device until a new marketing authorization is obtained.
BD actively maintains Quality Systems that establish standards for its product design, manufacturing, and distribution processes, in accordance with ISO standards and FDA regulation. These agencies engage in periodic reviews and inspections of BD’s quality systems, as well as product performance and advertising and promotional materials. These regulatory controls, as well as any changes in agency policies, can affect the time and cost associated with the development, introduction and continued availability of new and existing products. Where possible, BD anticipates these factors in its product development and planning processes. These agencies have the authority to take various administrative and legal actions against BD, such as product recalls, product seizures and other civil and criminal sanctions, for violations of applicable requirements. BD also undertakes voluntary compliance actions, such as voluntary recalls. In some cases, BD may determine that an identified product issue does not require a voluntary recall action. Should a regulator disagree with such a determination, the regulator may require BD to cease marketing of and recall the device until the issue has been corrected. In addition, BD may be required to seek an additional marketing authorization prior to marketing the corrected device.
BD also is subject to various federal and state laws, and laws outside the United States, concerning healthcare fraud and abuse (including false claims laws and anti-kickback laws), global anti-corruption, transportation, safety and health, and customs and exports. Many of the agencies enforcing these laws have increased their enforcement activities with respect to medical device manufacturers in recent years. This is part of a general trend toward increased regulation and enforcement activity within and outside the United States.
In addition, the federal government has enacted the Sunshine Act provisions requiring BD to publicly report gifts and payments made to physicians and teaching hospitals. Countries outside the United States have enacted similar local laws requiring medical device companies to report transfers of value to healthcare providers licensed in those countries. Failure to comply with these laws could result in a range of fines, penalties and/or other sanctions.
Consent Decree with FDA
Our U.S. infusion pump organizational unit is operating under an amended consent decree originally entered into by Cardinal Health 303, Inc. with the FDA in 2007 related to its Alaris™ SE infusion pumps. In 2009, the decree was amended (the “Consent Decree”) to include all infusion pumps manufactured by or for CareFusion 303, Inc., which was acquired by BD in 2015. CareFusion 303, Inc. remains the legal manufacturer of BD Alaris™ infusion pumps. The Consent Decree does not apply to intravenous administration sets and accessories.
Following an inspection that began in March 2020 of our Medication Management Systems facility in San Diego, California (CareFusion 303, Inc.), the FDA issued a Form 483 Notice (the “2020 Form 483 Notice”) that contained a number of observations regarding the site’s compliance with FDA’s Quality System, reporting of corrections and removals, and Medical Device Reporting (MDR) regulations. In December 2021, the FDA issued to CareFusion 303, Inc. a letter of non-compliance with respect to the Consent Decree (the “Non-Compliance Letter”) stating that, among other things, it had determined that certain of the corrective actions with respect to the 2020 Form 483 Notice appeared to be adequate, some were still in progress such that adequacy could not be determined yet, and certain others were not adequate (e.g., complaint handling and
7

Table of Contents
corrective and preventive actions, design verification and medical device reporting). Per the terms of the Non-Compliance Letter, CareFusion 303, Inc. provided the FDA with a proposed comprehensive corrective action plan (“CAP”) and has retained an independent expert to conduct periodic audits of the CareFusion 303, Inc. infusion pump facilities through 2025. CareFusion 303, Inc. has and will continue to update its CAP to address any observations that may arise during the course of these audits.
In addition, CareFusion 303, Inc. received an additional Form 483 Notice in May 2024 following an FDA inspection (“2024 Form 483 Notice”) that contained observations related to the site’s compliance with the FDA’s quality system regulations and MDR regulation related to its Infusion quality management system (covered by the Consent Decree) and separate Dispensing quality management system (which is not subject of the Consent Decree). On November 22, 2024, BD received a Warning Letter from the FDA, which is limited to CareFusion 303, Inc.’s Dispensing quality management system and BD PyxisTM products (“Dispensing Warning Letter”). See “— FDA Warning Letters” below for further information.
The FDA’s review of our responses to the observations specific to the Infusion quality management system in the 2024 Form 483 Notice and the CAP is ongoing, and no assurances can be given regarding further action by the FDA as a result of the observations, including but not limited to action pursuant to the Consent Decree, or that corrective actions proposed by CareFusion 303, Inc. will be adequate to address these observations. Additionally, we cannot currently predict the amount of additional monetary investment that will be incurred to resolve this matter or the matter’s ultimate impact on our business.
The Consent Decree authorizes the FDA, in the event of any violations in the future, to order us to cease manufacturing and distributing infusion pumps, recall products and take other actions. We may be required to pay damages of $15,000 per day per violation if we fail to comply with any provision of the Consent Decree, up to $15 million per year.
We may be obligated to pay more costs in the future because, among other things, the FDA may determine that we are not fully compliant with the Consent Decree and Non-Compliance Letter and therefore impose penalties under the Consent Decree, and/or we may also be subject to future proceedings and litigation relating to the matters addressed in the Consent Decree, including, but not limited to, additional fines, penalties, other monetary remedies, and expansion of the terms of the Consent Decree. As of September 30, 2024, we do not believe that a loss is probable in connection with the Consent Decree, and accordingly, we have no accruals associated with compliance with the Consent Decree.
As previously disclosed, on July 21, 2023, BD received 510(k) clearance from the FDA for its updated BD Alaris™ Infusion System, which enables both remediation and a return to market for the BD Alaris™ Infusion System. This clearance covers updated hardware features for Point-of-Care Unit (PCU), large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring and auto-identification modules. It also covers a new BD Alaris™ Infusion System software version with enhanced cybersecurity, along with interoperability features that enable smart, connected care with electronic medical record systems. To address all open recalls and ensure all devices at customer sites are running the most recent version of the BD Alaris™ Infusion System Software, all of the current BD Alaris™ Infusion System devices in the U.S. market will be remediated or replaced with the updated 510(k) cleared version over the next several years.
FDA Warning Letters
On January 11, 2018, BD received a Warning Letter from the FDA with respect to our former BD Preanalytical Systems ("PAS") unit, citing certain alleged violations of quality system regulations and of law. The Warning Letter states that, until BD resolves the outstanding issues covered by the Warning Letter, the FDA will not approve any premarket submissions for Class III devices to which the non-conformances are reasonably related or grant requests for certificates to foreign governments. BD has worked closely with the FDA and implemented corrective actions to address the quality management system concerns identified in the Warning Letter. In March 2020, the FDA conducted a subsequent inspection of PAS, which it classified as
8

Table of Contents
Voluntary Action Indicated, which means the FDA will not take or recommend any administrative or regulatory action as a result of the unit’s response to the observations associated with the quality management concerns in the inspection. BD continues to work with the FDA to generate additional clinical evidence and file 510(k)s as remaining commitments associated with the Warning Letter. As of September 30, 2024, BD has received seven FDA clearances. The FDA review of these remaining commitments is ongoing, and no assurances can be given regarding further action by the FDA as a result of these commitments, including but not limited to action pursuant to the Warning Letter.
As noted above, on November 22, 2024, BD received the Dispensing Warning Letter following an inspection of its facility located in San Diego, California, citing certain alleged violations of the quality system regulations, MDR regulation, the corrections and removals reporting regulation and law. The Dispensing Warning Letter states that, until BD resolves the outstanding issues covered by the Dispensing Warning Letter, the FDA will not approve any premarket submissions for Class III devices and may not grant requests for certificates to foreign governments concerning devices to which the non-conformances are reasonably related. As requested by the Dispensing Warning Letter, BD is preparing a comprehensive response to address FDA’s feedback in the Dispensing Warning Letter, which may include implementing additional corrective actions; however, no assurances can be given regarding further action by the FDA as a result of the noted non-conformities, or that corrective actions proposed and taken by CareFusion 303, Inc. will be adequate to address the non-conformities. Any failure to adequately address the Dispensing Warning Letter may result in regulatory actions initiated by the FDA without further notice, which may include, but are not limited to, seizure, injunction and civil monetary penalties. As a result, the ultimate resolution of the Dispensing Warning Letter and its impact on the Company’s operations is unknown at this time. In connection with the receipt of the Dispensing Warning Letter, the Company recorded an accrual in the fourth quarter of fiscal year 2024. See Note 6 to the consolidated financial statements in “Item 8. Financial Statements and Supplementary Data.” It is possible that the amount of the Company’s liability could exceed its currently accrued amount.
Ethylene Oxide/Sterilization
On October 28, 2019, BD entered into a consent order with the Environmental Protection Division of the Georgia Department of Natural Resources (the “EPD”), following the filing of a complaint and motion for temporary restraining order by the EPD seeking to enjoin BD from continuing sterilization operations at its Covington, Georgia facility. Under the terms of the consent order, which has been amended two times upon mutual agreement of BD and EPD, BD voluntarily agreed to a number of operational changes at its Covington and Madison, Georgia facilities, as well as at its distribution center in Covington, designed to further reduce ethylene oxide emissions, including but not limited to operating at a reduced capacity until successful implementation of fugitive emission control technology, ongoing ambient air monitoring and operational controls at such facilities. Following submission of data relating to the implementation of these operational changes, BD was permitted to return to normal operations in December 2021 at its facilities in Georgia in accordance with the operating conditions set forth in its permit applications, including a condition to continue ambient air monitoring. The final air permits for (i) the Covington and Madison facilities and (ii) the Covington distribution center were issued by the EPD on May 5, 2023, and July 2, 2024, respectively. By correspondence dated September 6, 2024, the EPD notified BD that the consent order had been terminated by the full and complete performance of each condition.
At a broader level, there is increased focus on the use and emission of ethylene oxide by the U.S. Environmental Protection Agency (“EPA”) and state environmental regulatory agencies. Additional regulatory requirements associated with the use and emission of ethylene oxide may be imposed in the future, either domestically or outside the U.S. Ethylene oxide is the most frequently used sterilant for medical devices and healthcare products in the U.S., and in certain cases is the only option to sterilize critical medical device products for the safe administration to patients. Any such increased regulation could require BD or sterilization service providers, including providers used by BD, to temporarily suspend operations to install additional emissions control technology, limit the use of ethylene oxide or take other actions, which would impact BD’s operations and further reduce the available capacity to sterilize medical devices and healthcare products, and could also result in additional costs. To this end, BD has proactively installed fugitive emissions controls at our
9

Table of Contents
facilities in East Columbus, NE and Sandy, UT. On April 5, 2024, the final National Emission Standards for Hazardous Air Pollutants (“NESHAP”): Ethylene Oxide Emissions Standards for Sterilization Facilities regulation issued by the EPA became effective. Companies generally have two years from the effective date to comply with the new requirements of the NESHAP. We are in the process of implementing certain changes to our facilities in accordance with NESHAP’s requirements, and such measures will require additional implementation and ongoing operational costs, including investments in certain new technologies.
In addition, on April 13, 2023, the EPA published a Pesticide Registration Review; Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide (“PID”). The EPA has not yet finalized the PID, which regulates the use of ethylene oxide as a sterilant and is intended to mitigate any human health and environmental risks associated with its use. We cannot predict what the final PID adopted by the EPA may require and therefore we are not able to assess the impact on our sterilization facilities, on the third-party sterilization facilities that BD utilizes and on our operations more generally.
If any new or existing regulatory requirements or rulemaking result in the suspension, curtailment or interruption of sterilization operations at BD or at medical device sterilizers used by BD, or otherwise limit the availability of third-party sterilization capacity, this could interrupt or otherwise adversely impact production of certain of our products or lead to civil litigation or other claims against BD. BD has business continuity plans in place to mitigate the impact of any such disruptions, although these plans may not be able to fully offset such impact, for the reasons noted above.
For further discussion of risks relating to the regulations to which we are subject, see Item 1A. Risk Factors.
Human Capital Management
At BD, our associates are guided by our purpose of advancing the world of healthTM and The BD WAY, our cultural foundation that encompasses our core values, servant leadership expectations and the mindset we bring to our work. Our associates are empowered to contribute their unique ideas and experiences to fuel innovation and improve patient outcomes. As of September 30, 2024, BD is comprised of approximately 74,000 associates located in 61 countries. Attracting, developing and retaining talented people in all different functions is crucial to executing our strategy and our ability to compete effectively in a highly competitive medical technology industry. Our ability to recruit and retain such talent depends on several factors, including compensation and benefits, talent development and career opportunities, and our unique culture. To that end, we continually invest in our associates to be an employer of choice.
Inclusion, Diversity & Equity
For BD, diversity refers to the practice of including the many communities and backgrounds that make up our Company and the world we serve. Diversity reflects our culture of inclusion, welcoming people of all different ethnicities, abilities, cultures, genders, religions, ages, sexual orientation, identity, experiences and tenure, as well as people with diverse opinions, perspectives, lifestyles, and ideas. Our associates possess a broad range of beliefs and experiences which have helped BD achieve our leadership position in the medical technology industry and the global marketplace. A key component of our journey to continually build a better BD is our commitment to global inclusion, diversity and equity (“ID&E”). We believe this commitment, coupled with our purpose and culture, allows us to better understand patient and customer needs and develop innovative technologies to meet those needs.
Each year, we establish annual corporate ID&E goals focused on fostering an inclusive workplace — fair treatment, equal access and opportunity, and acceptance for everyone. In addition, our executive leaders serve as sponsors to our nine global Associate Resource Groups (“ARGs”) that enable all associates to contribute their talents and skills to help advance opportunity for everyone. Our ARGs are empowered to set strategic goals aligned with their mission and centered around efforts to advance our company, local communities and each BD associates’ career, while fostering a sense of belonging, allyship, and professional development opportunities.
10

Table of Contents
Externally, we are building on our existing momentum and remain involved in efforts to help the medical technology industry in supporting ID&E by improving health equity and expanding access, including by partnering with the Advanced Medical Technology Association (“AdvaMed”). We remain committed to sustaining meaningful, long-term strategic partnerships and programs to help address equitable access to care and advance the health of our communities around the world. This work impacts under-resourced communities, both in developed and underdeveloped countries. Through the recently launched BD Community Investment Fund, we are investing over $2 million across more than 25 communities in FY2025, where BD has a significant footprint and share of the employment market. Grant recipients are community-based nonprofits with missions that are strategically aligned to BD’s health equity strategy and are working to address equal access to healthcare and social determinants of health in their communities.
BD also has a longstanding history of associate volunteerism that is enabled through our public-private partnerships and collaborations with non-government organizations. We sponsor volunteer service trips and other meaningful volunteer opportunities to help strengthen health systems and enable an environment that can maintain critical competencies and resources needed to improve delivery of care. Associates are empowered to serve organizations and causes that are important to them in their local communities. This includes a matching gift program, paid time off to volunteer, and an award program to give grants to non-profit organizations in honor of associates who engage in exceptional volunteer efforts.
These collective efforts have garnered recognitions including being named among Fortune’s most innovative companies and by TIME as one of the world’s best companies. BD received the Business Group on Health "Best Employers: Excellence in Health & Well-being Award" for its commitment to advancing employee well-being, and was recognized as a best place to work for disability inclusion for the sixth consecutive year. In addition, the company was named among America’s Climate Leaders by USA TODAY; the 100 Best Corporate Citizens by 3BL, ranking second in the healthcare equipment and services industry for the second consecutive year. We remain committed and accountable to the work required within our company and beyond our corporate walls to build and maintain equity, acceptance, and accessibility for everyone.
BD 2024 Workforce Diverse Representation
Gender (Global) Year-Over-Year Change Race (U.S. Only) Year-Over-Year Change
Executive 29% (1.0)% 23% +0.1%
Management 42% +0.7% 30% +0.2%
All associates 49% +0.1% 42% (0.8)%
For the above table, we define “executives” as associates in positions of vice president and above. “Management” positions are defined as those in manager, director or equivalent roles. Ratios are determined by dividing the number of diverse associates by the total number of associates including associates who have not disclosed race and/or gender. Year-over-year change is a percentage point.
Associate Growth and Development
At BD we hold ourselves and each other accountable for learning and growing every day, which underscores our growth mindset culture. Our commitment to continuous improvement helps us become the best version of ourselves and we invest significant resources to develop talent with the right capabilities to deliver the growth and innovation needed to support our strategy and customers, both for today and for the future. Our enhanced Strategic Organizational Planning process is focused on building the organizational capabilities required in the years to come, and we offer associates and managers a robust offering of tools to help in their personal and professional development, including career development plans, mentoring programs, and in-house learning opportunities, including BD University, our in-house continuing education curriculum delivered through a "leaders-as-teachers" approach. We remain committed to investing in our next generation of leaders, including by offering our associates a number of leadership development programs, designed to enable our BD
11

Table of Contents
culture, cultivate leadership, and develop key organizational skills. We take an inclusive approach to delivering such programs, providing content in various formats that include digital, virtual, and in person. Through these learning opportunities, we aim to help our associates learn when and how they like. Our robust manager curriculum is designed to help our more than 8,000 people managers become more effective servant leaders who are equipped with resources to create work environments that facilitate growth and success. We have also applied our growth mindset philosophy to our performance management approach with an increased focus on continuous learning and development to help us all achieve our best.
Associate Engagement
As we strive to be an employer of choice, we believe it is critical that our associates are informed, engaged, and can provide feedback. We communicate frequently and transparently with our associates through a variety of communication methods, including video and written communications, town hall meetings, associate surveys, and our company intranet, and acknowledge individual contributions to BD through a number of rewards and recognition award programs.
Our efforts to seek ongoing feedback help us better understand what we are doing well and how we can improve the associate experience. In addition to encouraging a speak-up culture between associates, their managers, and cross-functional teams, we conduct employee engagement surveys to provide all associates with an opportunity to share their perspectives and we take appropriate action in response.
In addition to helping associates stay engaged, we also work to foster and reinforce an inclusive culture where diverse perspectives are valued. This year, our ARGs continued to host company-wide dialogues and panel sessions to advance our business and cultural priorities and engage and foster conversations and awareness among associates.
Compensation, Benefits and Well-being
Our total rewards program is designed to attract and retain top talent and to incentivize performance aligned with our business strategy and values. We offer a comprehensive total rewards program aimed at promoting overall well-being in support of the varying health, home-life, and financial needs of our diverse and global associates. Through our integrated global approach to well-being, we provide support, education, and resources to empower associates across all geographies to prioritize their well-being and build resilience in the physical, emotional, financial, and social areas of life. To enable associates to take action in support of their overall well-being, our total rewards packages (which vary by location) include market-competitive pay, broad-based stock grants and bonuses, healthcare benefits and retirement savings plans, paid time off and family leave, flexible work schedules, on-site health and fitness centers, free physicals and flu vaccinations, well-being education and resources, employee assistance programs and other mental health support and resources. Each year we review and implement program enhancements and investments to ensure our benefits are inclusive and representative of the needs of BD associates and their families. Additionally, over the last several years in the U.S., we have increased efforts to mitigate the impact of rising healthcare costs and to offer more cost effective benefit options, with a specific focus on affordability for BD associates earning $55,000 per year or less.
BD is also committed to compensating all associates fairly and equitably for their contributions to company performance. Aligned with our priority focus on pay equity, we regularly conduct comprehensive audits, internal and external analyses, salary benchmarking and bias assessments to identify and remedy unexplained disparities.
12

Table of Contents
Available Information
BD maintains a website at www.bd.com. BD makes available its Annual Reports on Form 10-K, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K (and amendments to those reports) as soon as reasonably practicable after those reports are electronically filed with, or furnished to, the Securities and Exchange Commission (“SEC”). These filings may be obtained and printed free of charge at www.bd.com/investors.
In addition, the written charters of the Audit Committee, the Compensation and Human Capital Committee, the Corporate Governance and Nominating Committee, the Executive Committee and the Quality and Regulatory Committee of the Board of Directors, BD’s Corporate Governance Principles and its Code of Conduct, are available and may be printed free of charge at BD’s website at https://investors.bd.com/corporate-governance. Printed copies of these materials, this 2024 Annual Report on Form 10-K, and BD’s reports and statements filed with, or furnished to, the SEC, may also be obtained, without charge, by contacting the Corporate Secretary, BD, 1 Becton Drive, Franklin Lakes, New Jersey 07417-1880, telephone 201-847-6800. In addition, the SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov.
BD also routinely posts important information for investors on its website at www.bd.com/investors. BD may use this website as a means of disclosing material, non-public information and for complying with its disclosure obligations under Regulation FD adopted by the SEC. Accordingly, investors should monitor the Investor Relations portion of BD’s website noted above, in addition to following BD’s press releases, SEC filings, and public conference calls and webcasts. Our website and the information contained therein or connected thereto shall not be deemed to be incorporated into this Annual Report.
Forward-Looking Statements
BD and its representatives may from time-to-time make certain forward-looking statements in publicly-released materials, both written and oral, including statements contained in filings with the SEC and in its reports to shareholders. Additional information regarding BD’s forward-looking statements is contained in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Item  1A.    Risk Factors.
An investment in BD involves a variety of risks and uncertainties. The following describes some of the material risks that could adversely affect BD’s business, financial condition, operating results or cash flows. We may also be adversely impacted by other risks not presently known to us or that we currently consider immaterial.
Business, Economic and Industry Risks
Global economic conditions, including inflation and supply chain disruptions, could continue to adversely affect our operations.
General global economic downturns and macroeconomic trends, including heightened inflation, capital market volatility, interest rate and currency rate fluctuations, economic slowdown or recession, have contributed to conditions that have impacted, and may continue to impact, demand for our products and services, or the prices we can charge for our products, disrupt aspects of our supply chain, impair our ability to produce our products, increase borrowing costs and exacerbate other risks that affect our business, financial condition and results of operations. In addition, general economic conditions may impact the healthcare industry, including reductions in capital spending, changes in the delivery of healthcare services and increasing labor disputes or shortages, which could in turn affect demand for our products and services. Both domestic and international markets experienced inflationary pressures in fiscal year 2024 and we expect inflation to persist in the future but at lower levels than in recent years. In addition, currency exchange rates have been especially volatile in the recent past, and these currency fluctuations have affected, and may continue to affect, the reported value of our
13

Table of Contents
assets and liabilities, as well as our cash flows.
We have also experienced, and may continue to experience, challenges in our global supply chain, including shortages in supply, or disruptions in production and shipments, of certain materials or components used in our products, and related price increases. While to date, we have been able to manage the challenges associated with these delays and shortages without significant disruption to our business, no assurance can be given that these efforts will continue to be successful.
Our international operations subject us to certain business risks.
A substantial amount of our sales come from our operations outside the U.S., and we intend to continue to pursue growth opportunities in foreign markets, especially in emerging markets. Our foreign operations subject us to certain commercial, political and financial risks. In addition to fluctuations in foreign currency exchange (discussed above), our business in these foreign markets is subject to changing political, social, and geopolitical conditions, such as the evolving situations in Ukraine, the Middle East and Asia. These conditions include instability resulting from war, terrorism, insurrections and civil unrest, political conflict, and changing economic conditions, such as inflation, deflation, interest rate volatility and credit availability. Additionally, a number of factors, including U.S. relations with or among the governments of the foreign countries in which we operate, changes to international trade agreements and treaties, changes in tax laws and regulations, economic sanctions, export controls, restrictions on the ability to transfer capital across borders, tariffs and other increases in trade protectionism and barriers to market participation, or the weakening or loss of certain intellectual property rights in some countries, may affect our business, financial condition and results of operations. Foreign regulatory requirements, including those related to the testing, authorization, and labeling of products and import or export licensing requirements, could affect the availability of our products in these markets. In addition to these broader market conditions, our operations may also be impacted by a variety of local factors, such as competition from local companies, local product preferences and requirements, changes in local healthcare payment systems and healthcare delivery systems, changes resulting from new political administrations, and labor force instability.
The success of our operations outside the U.S. also depends, in part, on our ability to make necessary infrastructure enhancements to, among other things, our production facilities and sales and distribution networks and manage and staff widespread international operations. These and other factors may adversely impact our ability to pursue our growth strategy in these markets.
In addition, our international operations are governed by the U.S. Foreign Corrupt Practices Act and similar foreign anti-corruption laws. Global enforcement of anti-corruption laws has increased substantially in recent years, with more enforcement proceedings by U.S. and foreign governmental agencies and the imposition of significant fines and penalties. While we have implemented policies and procedures relating to compliance with these laws, our international operations, which often involve customer relationships with foreign governments, create the risk that there may be unauthorized payments or offers of payments made by employees, consultants, sales agents or distributors. We are also subject to certain U.S. and foreign laws and regulations that restrict BD from transacting business with, or making investments in, certain countries, governments, entities and individuals subject to U.S. or foreign economic sanctions or export restrictions. Any alleged or actual violations of these laws may subject us to government investigations and significant criminal or civil sanctions and other liabilities, and negatively affect our reputation and could result in a material adverse effect on our business, results of operations, financial condition and cash flows.

The medical technology industry is very competitive.
We are a global company that faces significant competition from a wide range of existing competitors and new market entrants. These include large medical device companies with multiple product lines, some of which may have greater financial and other resources than we do, as well as firms which are more specialized than we are with respect to particular markets or product lines. Nontraditional entrants, such as technology companies, are also entering into the healthcare industry and some may have greater financial and other
14

Table of Contents
resources than we do. We face competition across all our product lines and in each market in which our products are sold on the basis of product features, clinical or economic outcomes, product quality, availability, price, services and other factors.
Our ability to compete is also impacted by changing customer and patient preferences and requirements, including increased focus on products using materials of concern and demand for more sustainable products, and for products incorporating digital capabilities, including artificial intelligence, as well as changes in the ways healthcare services are delivered, such as the transition of more care from acute to non-acute settings and increased focus on chronic disease management. In particular, the shift of care from acute to non-acute settings may also place financial pressure on hospitals and broader healthcare systems that could result in less demand for our products and services. Cost containment efforts by governments and the private sector are also resulting in increased emphasis on products that reduce costs, improve clinical results and expand patient access. In addition, changes in regulatory or market standards, including, without limitation, cybersecurity requirements, often require significant investment to maintain compliance to relevant standards. Our ability to remain competitive will depend on how well we meet these changing market and regulatory demands in terms of our product offerings and go-to-market approaches.
The medical technology industry is also subject to rapid technological change, discovery and frequent product introductions. The development of new or improved products, processes or technologies by other companies that provide better features, pricing, clinical outcomes or economic value may render our current products or subsequently developed products obsolete or less competitive. In some instances, competitors, including pharmaceutical companies, also offer (or are attempting to develop) alternative therapies for disease states that may be delivered without a medical device. Lower cost producers have also created pricing pressure, particularly in developing markets.
The medical technology industry has also experienced a significant amount of consolidation, resulting in companies with greater scale and market presence than BD. Traditional distributors are also manufacturers of medical devices, providing another source of competition. In addition, healthcare systems and other providers are consolidating, resulting in greater purchasing power for these companies. As a result, competition among medical device suppliers to provide goods and services has increased. Group purchasing organizations and integrated health delivery networks have also served to concentrate purchasing decisions for some customers, which has led to downward pricing pressure for medical device suppliers. Further consolidation in the industry could intensify competition among medical device suppliers and exert additional pressure on the demand for and prices of our products.
We are subject to foreign currency exchange risk.
A substantial amount of our revenue is derived from international operations, and we anticipate that a significant portion of our future sales will continue to come from outside the U.S. The revenues we report with respect to our operations outside the U.S. have been and may continue to be adversely affected by fluctuations in foreign currency exchange rates, which are caused by a number of factors, including changes in a country's political and economic policies and inflationary conditions. Furthermore, currency exchange rates have been especially volatile in the recent past, and these currency fluctuations have affected, and may continue to affect, the reported value of our assets and liabilities, as well as our cash flows. A discussion of the financial impact of exchange rate fluctuations and the ways and extent to which we may attempt to address any impact is contained in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. Any exchange rate hedging activities we engage in may only offset a portion of the adverse financial impact resulting from unfavorable changes in foreign currency exchange rates. We cannot predict with any certainty changes in foreign currency exchange rates or the degree to which we can effectively mitigate these risks.
15

Table of Contents
Market dynamics, changes in reimbursement practices and coverage policies and third-party payer cost containment measures could affect the demand for our products and the prices at which they are sold.
The sale of our products and services, as well as access to them, depends, in part, on the healthcare funding landscape and how healthcare providers and facilities are reimbursed by public and private payers. Coverage policies and reimbursement levels can vary across the payer community globally, regionally, and locally, and may affect which products customers purchase, the market acceptance rate for new technologies and the prices customers are willing to pay for those products in a particular jurisdiction. In addition, third-party payers are increasingly challenging the reimbursement models and prices charged for medical products and services. Any changes to the reimbursement landscape, or adverse decisions relating to our products by administrators of these systems could significantly reduce reimbursement for procedures using our products or result in denial of reimbursement for those products, which could adversely affect customer demand, or the price customers are willing to pay for such products. See “Third-Party Reimbursement” under “Item 1. Business.”
A global trend towards limiting growth of healthcare costs may also put industry-wide pressure on medical device or clinical diagnostic pricing. In the U.S., these include value-based purchasing and managed care arrangements. Governments in China and other countries continue to use various mechanisms to control healthcare expenditures, including increased use of competitive bidding and tenders, price regulation (such as volume-based procurement programs (“VoBP”)), government imposed payback provisions, and changes in reimbursement practices and policies on average selling prices for our products, which have unfavorably impacted our revenues and may continue to impact our results of operations in certain countries.
Our future growth is dependent in part upon the development of new products, and there can be no assurance that such products will be developed.
A significant element of our strategy is to increase revenue growth by focusing on innovation and new product development. New product development requires significant investment in R&D, clinical trials and regulatory approvals. The results of our product development efforts may be affected by a number of factors, including our ability to anticipate customer needs, innovate and develop new products and technologies, successfully complete clinical trials, obtain regulatory approvals and reimbursement in the U.S. and abroad, manufacture products in a cost-effective manner, obtain appropriate intellectual property rights, and gain and maintain market acceptance of our products. In addition, patents attained by others can preclude or delay our commercialization of a product. There can be no assurance that any products now in development, or that we may seek to develop in the future, will achieve technological feasibility, obtain regulatory approval or gain market acceptance. If we are unable to develop and launch new products, our ability to maintain or expand our market position in the markets in which we participate may be negatively impacted. Even if we successfully develop new products or enhancements or new generations of existing products, they may be quickly rendered obsolete by changing customer preferences, changing industry or regulatory standards, or competitors’ innovations.
We are subject to risks associated with public health crises, such as pandemics and epidemics, which could have a material adverse effect on our business. The nature and extent of impacts from any such events are highly uncertain and unpredictable.
We are subject to risks associated with public health crises, such as pandemics and epidemics. Such events could result in preventative or protective measures or other actions by governments and private health institutions that could negatively impact local or global economic conditions and result in reductions in the demand for certain of our products, negatively impacting our business, financial condition and results of operations.
In addition, public health crises could result in significant volatility in our global supply chain network, including shortages in supply or disruptions or delays in shipments, as well as price increases, of certain materials or components used in our products and increases in transportation costs.
16

Table of Contents
The scope and duration of any future public health crisis, the pace at which government restrictions are imposed and lifted, the scope of additional actions taken to mitigate the spread of disease, global vaccination and booster rates, the speed and extent to which global markets and utilization rates for our products fully recover from the disruptions caused by such a public health crisis, and the impact of these factors on our business, financial condition and results of operations, will depend on future developments that are highly uncertain and cannot be predicted with confidence.
To the extent any such public health crises affect our operations and global economic conditions more generally, it may also have the effect of heightening many of the other risks described herein.
Reductions in customers’ research budgets or government funding may adversely affect our business.
We sell products to researchers at pharmaceutical and biotechnology companies, academic institutions, government laboratories and private foundations. Research and development spending of our customers can fluctuate based on spending priorities and general economic conditions. A number of these customers are also dependent for their funding upon grants from U.S. government agencies, such as the U.S. National Institutes of Health, and similar agencies in other countries. The level of government funding of research and development is unpredictable. The availability of governmental research funding may be adversely affected by economic conditions and governmental spending reductions, particularly during periods of economic uncertainty. Any reduction or delay in governmental funding could cause our customers to delay or forgo purchases of our products.
We need to attract and retain key employees to be competitive.
Our ability to compete effectively depends upon our ability to attract and retain executives, key employees and other associates. Competition for experienced employees, particularly for persons with certain technical competencies in some geographies, can be a challenge. Additionally, we need qualified managers and skilled employees with technical, manufacturing and distribution experience to operate our business successfully. Our ability to recruit and retain such talent will depend on a number of factors, including how BD’s compensation, benefits, work location, corporate culture and work environment compares with those offered by our competitors and other local employers. While there has been a slight improvement in what had been an intensely competitive labor market, there continues to be pressure on skilled labor in certain markets. A sustained labor shortage or increased turnover rates within our employee base has led to, and may continue to lead to, increased costs, such as an increase in overtime necessary to meet demand and increased wages and benefit costs to attract and retain skilled employees, and could negatively affect our ability to efficiently operate our manufacturing and distribution facilities and overall business. If we cannot effectively recruit and retain qualified executives and skilled employees, we could encounter operational disruptions or other negative consequences to our business, financial condition or results of operations.
Operational Risks
Cybersecurity incidents and breaches or breakdowns of our information and technology systems or infrastructure could have a material adverse effect on our operations.
We rely on a large number of information and technology (“IT”) systems and related infrastructure, including services provided to us by third-party vendors to operate our business. We collect, use, store, transfer and otherwise process electronic information in our day-to-day operations, including personal, confidential, or proprietary information of BD and its customers, vendors and other business partners, and patients. Some of our products and systems collect personal, confidential or proprietary information regarding patients and patient therapy on behalf of our customers and some of our products are internet enabled or connect to our IT systems for maintenance and other purposes. We also have products and systems that connect to the internet, hospital networks, electronic medical record systems or electronic health record systems. In addition, we rely on networks and services, including internet sites, cloud and software-as-a-service (“SaaS”) solutions, platform-as-a-service (“PaaS”) solutions, data hosting and processing facilities, artificial intelligence, tools and other hardware, software (including open-source software) and technical applications and platforms, including some
17

Table of Contents
that are managed, hosted, provided and/or used by third-party vendors, to operate our business. Further, we expect that the breadth and complexity of our IT systems and infrastructure will increase as we expand our product offerings to utilize cloud technologies and potentially artificial intelligence, which present inherent enterprise technology risks, including those related to privacy, data protection and cybersecurity, that need to be managed. The foregoing could expose us to further risk of potential breaches, failures, interruptions and disruptions.
While we are continuing to modernize our IT systems and infrastructure (such as hardware, software and operating systems), there are still technologies in operation that are more vulnerable to risk of failures, interruptions and disruptions. In addition, while we continue to enhance business continuity and disaster recovery plans and strategies, there is no guarantee that such plans and strategies will be effective or account for all eventualities. We have experienced, and could in the future experience, the failure, interruption or disruption of the functionality of our IT systems and infrastructure, or those of third-party vendors upon which we rely, which could impair our ability or that of our customers, suppliers and other business partners to conduct business, result in the loss of BD trade secrets or otherwise compromise personal, confidential or proprietary information of BD or its customers, suppliers and other business partners, or of patients, result in efficacy or safety concerns for certain of our products, result in reputational harm to our business and result in actions by regulatory bodies or civil litigation.
Cyberattacks continue to increase in frequency, sophistication and intensity, and are increasingly difficult to detect for periods of time, especially as they relate to attacks on third-party vendors. Such attacks are often carried out by motivated and highly skilled actors, who are increasingly well-resourced. Our IT systems and infrastructure, as well as those of various third parties on which we rely, have experienced, and are likely to continue to experience, a variety of cyberattacks, including, but not limited to, unauthorized access, malicious code execution and/or phishing attacks, which has resulted, and could in the future result, in our and our customers’ personal, confidential or proprietary information being accessed, destroyed, lost, stolen or otherwise compromised and increased costs for cybersecurity measures or remediation. For example, through our cybersecurity monitoring tools and processes, we recently identified incidents of unauthorized activity on a portion of our IT systems, in which certain information relating to BD’s IT infrastructure and service credentials for certain BD Diagnostics Solutions, BD PyxisTM, and Parata products utilized by laboratories, hospitals and pharmacies (the “Product Service Credentials”) were accessed and/or exfiltrated. After becoming aware of the incidents, BD terminated the unauthorized access, applied additional security measures, and is working with customers to update these Product Service Credentials. While an unauthorized party would have to penetrate a customer’s local network and, in some cases, may also need to be physically present at the instrument in order to use these Product Service Credentials, until these credentials are updated, there is a risk of unauthorized access that may impact the confidentiality, integrity and/or availability of the relevant products and associated systems or data. To date, we have not been made aware of any unauthorized use of these Product Service Credentials. As of the date of this filing, the incidents have not had, and we do not expect them to have, a material impact on BD’s overall business operations, financial condition or results of operations.
In addition, certain factors, such as growth through acquisitions, rapid technology evolution, including increased adoption of artificial intelligence, and geopolitical events, have increased cybersecurity risks. In this increasingly hostile environment, we, and our third-party vendors could experience, a loss, unauthorized access to or disclosure or other compromise of personal, confidential or proprietary information, including information regarding third parties, such as customers and patients, due to a number of causes, including, but not limited to, the exploitation of system vulnerabilities, cyberattacks, unauthorized access to our products, improper data handling, breakdowns of our IT systems and infrastructure or other cybersecurity incidents or breaches. These cybersecurity incidents and breaches could adversely affect our reputation, financial condition, results of operations or competitive position in the market and result in other significant negative consequences, including lost revenue, manufacturing challenges or disruption, diversion of management attention, litigation, regulatory action and damage to our relationships with vendors, business partners and customers.
18

Table of Contents
Unauthorized tampering, adulteration or interference with our products, including through cyberattacks, may also create issues with product functionality that could result in a loss of data, risk to patient safety and product recalls or field actions, as well as impact our compliance with privacy, data protection and other laws and regulations and could result in reputational damage and actions by regulatory bodies or civil litigation.
In addition, acquisitions, and the integration of acquired companies into the Company’s existing and future IT systems and infrastructure, including with third-party vendors and processes, inherently presents cybersecurity risks, such as exposing us to vulnerabilities and threats that were previously unknown or unmanaged. While we attempt to mitigate these risks through due diligence, risk assessments and the implementation of cybersecurity controls and protocols during and after the acquisition process, there can be no assurance that such measures will be sufficient to prevent, mitigate or remediate cybersecurity incidents or breaches, which could have a material adverse effect on our business, financial condition and results of operations.
While we have made investments intended to address threats presented by cybersecurity incidents and breaches, continue to dedicate significant resources intended to protect our products and systems from cybersecurity incidents and breaches, and continue to work with government authorities and third-party vendors to detect and reduce the risk of future cybersecurity incidents and breaches, there can be no assurances that these protective measures will be sufficient to prevent cybersecurity incidents or breaches that could have a material adverse impact on our business.
Cost volatility could adversely affect our operations.
Our results of operations could be negatively impacted by volatility in the cost of raw materials, components, labor, freight, energy and other production costs that, in turn, increases the costs of producing and distributing our products. New laws or regulations adopted in response to climate change could also increase energy, conversion and transportation costs, as well as the costs of certain raw materials and components. In particular, we purchase supplies of resins, which are oil-based components used to manufacture certain products, and any significant increase in resin costs, whether due to inflationary pressure, supply constraints, regulatory changes or otherwise, could adversely impact future operating results. Increases in oil prices can also increase our packaging and transportation costs. The costs of raw materials, transportation, construction, services, and energy necessary for the production and distribution of our products continues to increase and be volatile. These prices may continue to fluctuate based on many factors beyond our control. While we have implemented cost containment measures, progressed selective price increases and taken other actions to mitigate these inflationary pressures in our supply chain, we may not be able to completely offset all the increases in our operational costs.
A reduction or interruption in the supply of certain raw materials and components could adversely affect our operating results.
We purchase many different types of raw materials and components used in our products, some of which are not available from multiple sources. In addition, for quality assurance, cost-effectiveness and other reasons, certain raw materials and components are purchased from sole suppliers. The price and supply of these materials and components has been, and may in the future be, impacted or disrupted for reasons beyond our control, including supplier shutdowns, supplier capacity constraints, supplier insolvencies, labor disruptions or shortages, transportation delays, inflationary pricing pressures, work stoppages, extreme weather events, geopolitical developments, global economic uncertainty or downturns, sanctions and trade restrictions, and other governmental regulatory actions (such as in the area of materials of concern) and any such changes or disruptions could adversely affect our business, results of operations, financial condition and cash flows. We have experienced, and may continue to experience, significant challenges to our global transportation channels and other aspects of our global supply chain network, including to the cost and availability of energy, raw materials and components due to shortages, labor strikes, and cost inflation. We continuously explore
19

Table of Contents
alternative routes, transportation modes, and replenishment timings to preempt and mitigate associated risks, but no assurance can be given that these efforts will adequately address these challenges and disruptions.
While we work with suppliers to ensure continuity of supply and service, no assurance can be given that these efforts will be successful. In addition, due to regulatory requirements relating to the qualification of suppliers, we may not be able to establish additional or replacement sources on a timely basis or without excessive cost. The termination, reduction or interruption in supply of these raw materials and components could adversely impact our ability to manufacture and sell certain of our products, which could have an adverse impact on our business, financial condition and results of operations.
Interruption of our manufacturing or sterilization operations could adversely affect our business.
We have manufacturing sites all over the world. In some instances, however, the manufacturing of certain of our product lines is concentrated in one or a few of our plants. Interruption to our manufacturing operations resulting from system outages, cybersecurity incidents or breaches, weather or natural disasters, regulatory requirements, labor disruptions, equipment failure or other issues in our manufacturing process, could adversely affect our ability to manufacture our products. In some instances, we may not be able to transition manufacturing to other BD sites or a third party to replace the lost production. A significant interruption of our manufacturing operations could result in lost revenues and damage to our relationships with customers.
In addition, many of our products require sterilization prior to sale, and we utilize both BD facilities and third parties for this process. In some instances, only a few facilities are qualified under applicable regulations to conduct this sterilization. To the extent we or our third-party providers are unable to sterilize our products, whether due to lack of capacity, availability of materials for sterilization (including cobalt), regulatory requirements or otherwise, we may be unable to transition sterilization to other sites or modalities in a timely or cost-effective manner, or at all, which could have an adverse impact on our operating results and financial condition.
At a broader level, there is increased focus on the use and emission of ethylene oxide by the EPA and state environmental regulatory agencies. Additional regulatory requirements associated with the use and emission of ethylene oxide for sterilization may be imposed in the future, both domestically and outside the U.S. On April 5, 2024, the final National Emission Standards for Hazardous Air Pollutants (“NESHAP”): Ethylene Oxide Emissions Standards for Sterilization Facilities regulation issued by the EPA became effective. Companies generally have two years from the effective date to comply with the new requirements of the NESHAP. We are in the process of implementing certain changes to our facilities in accordance with NESHAP’s requirements, and such measures will require additional implementation and ongoing operational costs, including investments in certain new technologies.
In addition, on April 13, 2023, the EPA published a Pesticide Registration Review: Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide (“PID”). The EPA has not yet finalized the PID, which regulates the use of ethylene oxide as a sterilant and is intended to mitigate any human health and environmental risks associated with its use. We cannot predict what the final PID adopted by the EPA may require and therefore we are not able to assess the impact on our sterilization facilities, on the third-party sterilization facilities that BD utilizes and our operations more generally.
This increased regulation could require BD or sterilization service providers, including providers used by BD, to temporarily suspend operations to install additional emissions control technology, limit the use of ethylene oxide or take other actions, which would impact BD’s operations and further reduce the available capacity to sterilize medical devices and healthcare products, and could also result in additional costs. If any existing regulatory requirements or any such regulatory actions or rulemaking result in the suspension or interruption of sterilization operations at BD or at medical device sterilizers used by BD, or otherwise limit the availability of third-party sterilization capacity, this could interrupt or otherwise adversely impact production of certain of our products or lead to civil litigation or other claims against BD. BD has business continuity plans in
20

Table of Contents
place to mitigate the impact of any such disruption, although these plans may not be able to fully offset such impact, for the reasons noted above. See “Item 1. Business - Regulation” for a discussion of the consent order BD entered into with the Environmental Protection Division of the Georgia Department of Natural Resources and the risk related to sterilization operations generally.
Climate change, or legal, regulatory or market measures to address climate change, could adversely affect our business, financial condition or results of operations.
Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases (“GHG”) in the atmosphere may present risks to our business and operations. Extreme weather or other conditions, such as hurricanes, tornadoes, windstorms, wildfires or flooding, which may result from climate change could adversely impact our operations and supply chain, including the availability and cost of raw materials and components required for the operation of our business, and human capital issues for BD and companies within our supply chain. In addition, access to and pricing of certain natural resources, such as water, could impact our manufacturing operations. Such conditions could also result in physical damage to our products, plants and distribution centers, as well as the infrastructure and facilities of our suppliers and of hospitals, medical care facilities and other customers.
There has been increased focus by federal, international, state and local regulatory and legislative bodies to combat and/or limit the effects of climate change through a variety of means, including regulating GHG emissions (and requirements to disclose climate-related risks and metrics, including GHG emissions), policies mandating or promoting the use of renewable or zero-carbon energy and sustainability initiatives, and additional taxes on fuel and energy. There has been, and in the future there may be additional, legislation or regulations enacted or promulgated in the United States and in other jurisdictions in which we do business that impose more stringent restrictions and requirements on our operations than our historical legal or regulatory obligations as well as additional disclosure or reporting requirements. We have experienced, and companies in our supply chain may experience, increased compliance burdens and costs to meet the regulatory obligations. Such increased compliance burdens and costs could cause disruption in the sourcing, manufacturing and distribution of our products and adversely affect our business, financial condition or results of operations.
Additionally, the impacts of climate change may further influence customer and other stakeholder preferences and requirements. This includes increased demand for more sustainable products, including products with lower environmental footprints, and for companies to produce and demonstrate progress against sustainability goals and GHG reduction targets, including product-level GHG emissions data. Failure to meet stakeholder expectations or our own goals or commitments relating to sustainability or GHG emissions reductions, provide sustainable products or demonstrate GHG reductions could potentially result in loss of market share, reputational impacts, or an inability to attract and retain customers.
Legal, Quality and Regulatory Risks
We are subject to lawsuits.
We are or have been a defendant in a number of lawsuits, including, among others, purported class action lawsuits for alleged antitrust violations and violations of federal securities laws, environmental and product liability claims (including pending claims relating to ethylene oxide, our hernia repair implant products, surgical continence and pelvic organ prolapse products for women, vena cava filter products and implantable ports, which involve, or could in the future involve, lawsuits seeking class action status or seeking to establish multi-district litigation or other consolidated proceedings) and suits alleging patent infringement. We also are or have been subject to government investigations and civil investigative demands seeking information with respect to alleged violations of law, including in connection with federal and/or state healthcare programs (such as Medicare or Medicaid), the federal securities laws, federal contracting requirements and/or sales and marketing practices, among other things. A more detailed description of certain litigation to which we are a party is contained in Note 6 to the consolidated financial statements included in “Item 8. Financial Statements and Supplementary Data.” We could be subject to additional lawsuits, governmental investigations, subpoenas and civil investigative demands in the future. Any such lawsuits, governmental investigations, subpoenas and
21

Table of Contents
civil investigative demands could ultimately have a material adverse effect on our results of operations, financial condition and liquidity, and could distract management from the operations of the business.
Reserves established for estimated losses with respect to legal proceedings do not represent an exact calculation of our actual liability, but instead represent our estimate of the probable loss at the time the reserve is established to the extent future losses are probable and reasonably estimable. Due to the inherent uncertainty of litigation and our underlying loss reserve estimates, additional reserves may be established or current reserves may be significantly increased from time-to-time. Also, in some instances, we are not able to reasonably estimate the amount or range of loss that could result from an unfavorable outcome of the litigation to which we are a party. In view of these uncertainties, we could incur charges materially in excess of any currently established accruals and, to the extent available, excess liability insurance. In addition, even if the Company believes it has meritorious defenses, from time to time the Company engages in settlement discussions and mediation and considers settlements taking into account various factors including, among other things, developments in such legal proceedings and the resulting risks and uncertainties. These activities have resulted in settlements for certain matters and going forward could result in further settlements, any of which may be confidential and could be significant and result in charges in excess of accruals. Any such future charges, individually or in the aggregate, could have a material adverse effect on our results of operations, financial condition and/or liquidity.
With respect to certain litigation, we believe that some settlements and judgments, as well as legal defense costs, may be covered in whole or in part under applicable insurance policies with a limited number of insurance companies, or, in some circumstances, indemnification obligations owed to us by other parties. However, amounts recovered under these arrangements may be less than the stated coverage limits or less than otherwise expected and may not be adequate to cover damages and/or costs. In addition, there is no guarantee that insurers or other parties will pay claims or that coverage or indemnity will be otherwise available. Also, for certain product liability claims or lawsuits, BD does not maintain or has limited remaining insurance coverage, and we may not be able to obtain additional insurance on acceptable terms or at all that will provide adequate protection against potential liabilities.
We are subject to extensive regulation.
Our operations are global and are affected by complex state, federal and international laws relating to healthcare, environmental protection, occupational health and safety, antitrust, anti-corruption, marketing, fraud and abuse (including anti-kickback and false claims laws), export control, product safety and efficacy, employment, labor, privacy and data protection, taxation, artificial intelligence and other areas. Violations of these laws can result in criminal or civil sanctions, including substantial fines and, in some cases, exclusion from participation in healthcare programs such as Medicare and Medicaid. Environmental laws, particularly with respect to climate change and the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate closures of, or changes to, our manufacturing plants or processes or those of our suppliers, or result in liability to BD. The enactment of additional laws and reporting requirements in the future or changes in the interpretation of existing laws or regulations, may increase our compliance costs or otherwise adversely impact our operations and financial performance. For example, the FDA’s increased oversight of laboratory developed tests may impact certain of our customers and, as a result, could affect our financial performance.
We are subject to extensive regulation by the FDA pursuant to the Federal Food, Drug and Cosmetic Act, by comparable agencies in foreign countries, and by other regulatory agencies and governing bodies. Most of our products must receive authorization from the FDA or counterpart regulatory agencies in other countries before they can be marketed or sold. This process may require us to incur significant costs in terms of time and resources, and these costs have been increasing due to increased requirements from the FDA and comparable governing bodies for supporting data for submissions. The regulatory process may also require changes to our products or result in limitations on the indicated uses of our products. Governmental agencies may also impose new requirements regarding registration, including, but not limited to, labeling updates or changes to prohibited materials that require us to modify or re-register products already on the market or otherwise impact our ability
22

Table of Contents
to market our products in those countries. In addition, changes we have made, or may make in the future, to our products have been, or may in the future be, subject to U.S. or foreign regulatory review, including additional 510(k) clearance, PMA approval and other marketing authorizations (such as, but not limited to, with respect to BD AlarisTM pumps and related sets and BD VacutainerTM). We have made modifications to certain of our products in the past and have determined based on our review of our internal documentation and data and the applicable FDA or foreign regulations and guidance that in certain instances new 510(k) clearances or other premarket submissions were not required. We may make similar modifications or add additional features in the future that we believe do not require a new clearance or approval. If the FDA or a foreign regulator disagrees with our determinations, we may be required to cease marketing and/or to recall the modified product until we obtain a new marketing authorization, which could result in lost revenue, additional costs and damage to our reputation. Such non-compliance may also subject the Company to civil and criminal, monetary and non-monetary penalties, or other actions being taken with respect to products in the field. Marketing authorization and the time needed to secure such authorization is uncertain and we may not be able to obtain such authorization on the timeline or conditions we expect or at all. Our ability to obtain and maintain regulatory approvals from the FDA or foreign regulators may be difficult and could increase the cost of compliance and impact our ability to market our products.
Following the introduction of a product, these agencies also periodically review our manufacturing processes and product performance. Our failure to comply with the applicable good manufacturing practices, adverse event reporting and other post market requirements of these agencies could delay or prevent the production, marketing or sale of our products and result in delays or suspensions of regulatory clearances, warning letters or consent decrees, closure of manufacturing sites, import bans, seizures or recalls of products, civil or criminal sanctions and damage to our reputation. More stringent oversight by the FDA and other agencies in recent years has resulted in increased enforcement activity, which increases our compliance risk.
Our CareFusion 303, Inc. subsidiary is operating under a Consent Decree that affects our BD Alaris™ infusion pump business in the U.S. We are also currently operating under two warning letters issued by the FDA for our Dispensing and Specimen Management businesses. For more information regarding the consent decree and warning letters, see “Regulation” under Item 1. Business.
As previously disclosed, on July 21, 2023, BD received 510(k) clearance from the FDA for its updated BD Alaris™ Infusion System, which enables both remediation and a return to market for the BD Alaris™ Infusion System. In accordance with our commitments to the FDA, all of the current BD Alaris™ Infusion System devices in the U.S. market will be remediated or replaced with the updated 510(k) cleared version over the next several years. The overall timing and cost of replacement or remediation of the BD Alaris™ Infusion Systems and return to market in the U.S. may be impacted by, among other things, customer readiness, supply continuity, and our continued engagement with the FDA.
In addition, the European Union (“EU”) has adopted the EU Medical Device Regulation (the “EU MDR”) and the In Vitro Diagnostic Regulation (the “EU IVDR”), each of which impose stricter requirements for the marketing and sale of medical devices, including in the area of clinical evidence requirements, quality systems and post-market surveillance. The EU MDR has been fully operational for previously approved self-certified medical devices since May 2021. The application of the EU MDR has been extended until 2027 for certain devices considered higher-risk and to 2028 for other devices. This longer transition timeline applies only to devices that are transitioning to MDR and meet other specific conditions set out in the EU IVDR. The EU IVDR has been fully applicable for manufacturers of in vitro diagnostic medical devices since May 2022. Complying with and maintaining devices under these regulations requires us to incur significant expenditures. Additionally, the availability of EU notified body services certified to the new requirements is limited, which may delay the marketing approval for some of our products under the EU MDR. Any such delays, or any failure to meet these requirements could adversely impact our business in the EU and other regions that tie their product registrations to EU conformity requirements.
23

Table of Contents
We are also subject to complex and frequently changing privacy and data protection laws, rules and regulations in the U.S. and a significant number of other countries where BD operates, regarding the collection, use, storage, security, transfer and other processing of personal data. These laws, rules and regulations require companies to, among other things, proactively implement effective programs and enhance internal policies, business practices, processes, and controls and could impose significant limitations and additional compliance costs on us. In addition, these laws, rules and regulations require us to embed privacy, security and data protection requirements in all assets impacting the processing of personal data and could also require us to modify current or future products or services, which may harm our future financial results. Any actual or perceived noncompliance with these laws, rules and regulations, our internal policies and procedures or our contracts governing the processing of personal data could result in significant consequences for BD, including, among other things, business interruption, sanctions and significant pecuniary fines, regulatory inquiries and investigations, adverse publicity, loss of competitive advantage and customer trust, as well as privacy litigation and civil lawsuits with damages.
The importance of privacy and data protection laws, rules and regulations for the healthcare and med-tech industry specifically is constantly growing, as personal data is an integral part of doing business in our sector, and the legal standards are evolving and becoming more complex worldwide. A significant number of countries where we operate have enacted privacy or data protection laws, rules and regulations, the majority of which have extraterritorial scope, creating significant compliance challenges as we seek to maintain our global reach, with significant penalties for non-compliance, based on total worldwide annual revenue from the preceding financial year. In some cases, there are restrictions on the transfer of personal data outside the home country. More recently, privacy and data protection regulators are paying special attention to emerging issues linked to new digital technologies, such as the use of artificial intelligence, biometrics, and surveillance technologies, which pose unique challenges to existing privacy and data protection paradigms.
In addition, certain privacy and data protection laws, rules and regulations may apply to us indirectly through our customers, manufacturers, suppliers or other third-party partners. For example, non-compliance with applicable laws, rules or regulations by a third-party partner that is processing personal data on our behalf may be deemed non-compliant by us or a failure by us to conduct proper due diligence on the third party, which could result in material fines or litigation. We also could be subject to additional expenses and liabilities in the event of a cybersecurity incident or breach, or the failure of an IT system owned or operated by us or a third party with which we partner or its vendor.
Finally, changes in the tax laws and regulations of the jurisdictions in which we operate could increase our tax expense and/or tax payments, increase tax uncertainty and have a material adverse impact on our results of operations. For example, the Organization for Economic Cooperation and Development (OECD) published Pillar Two Model Rules which impose a 15% minimum tax on income of large multinational enterprises in the jurisdictions in which they operate. Pillar Two is effective in some of the jurisdictions in which we operate beginning in fiscal year 2025. We continue to evaluate the impacts of the enacted Pillar Two legislation. Tax laws, inclusive of Pillar Two legislation, in the U.S. and in other countries in which we and our affiliates do business could change on a prospective or retroactive basis, and any such changes could have a material impact on our effective tax rate and on our business, results of operations, financial condition, and cash flows.
Defects or quality issues associated with our products could adversely affect the results of our operations.
The design, manufacture and marketing of medical devices involve certain inherent risks. Manufacturing or design defects, component failures, unapproved or improper use of our products, or inadequate disclosure of risks or other information relating to the use of our products can lead to injury or other serious adverse events. Such events have in the past and could in the future lead to recalls or safety alerts relating to our products (either voluntary or as required by the FDA or similar governmental authorities in other countries), and could result, in certain cases, in the removal of a product from the market. A recall could result in significant costs, lost sales and customers, enforcement actions and/or investigations by state and federal governments or other enforcement bodies, as well as negative publicity and damage to our reputation that could reduce future demand for our products. Personal injuries relating to the use of our products can also result in
24

Table of Contents
significant product liability claims being brought against us. In some circumstances, such adverse events could also cause delays in regulatory approval of new products or the imposition of post-market approval requirements.
Our operations are dependent in part on patents and other intellectual property assets.
Many of our businesses rely on patent, trademark and other intellectual property assets. These intellectual property assets, in the aggregate, are of material importance to our business. We can lose the protection afforded by these intellectual property assets through patent expirations, legal challenges or governmental action. Any patent applications we own or license may not result in patents being issued and any issued patents we obtain may not provide us with any competitive advantage. Furthermore, we may fail to accurately predict all of the countries where patent protection will ultimately be desirable, and if we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. Patents attained by competitors, particularly as patents on our products expire, may also adversely affect our competitive position. Competitors may design around our intellectual property to develop competing technologies and products without infringing our intellectual property rights. In addition, competitors may seek to invalidate patents on our products or claim that our products infringe upon, misappropriate or otherwise violate their intellectual property, which could result in a loss of competitive advantage or the payment of significant legal fees, damage awards and past or future royalties, as well as injunctions against future sales of our products. We also operate in countries that do not protect intellectual property rights to the same extent as in the U.S., which could make it easier for competitors to compete with us in those countries.
We also rely on trade secrets and proprietary know-how with which we seek to protect our products, in part, by confidentiality agreements with certain employees, consultants and other parties. These agreements may not adequately protect our trade secrets and other proprietary rights. These agreements may be breached and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently developed by our competitors.
The loss of a significant portion of our portfolio of intellectual property assets may have an adverse effect on our earnings, financial condition or cash flows.
Risks Relating to Our Indebtedness
We may not be able to service all of our indebtedness.
We depend on cash on hand and cash flows from operations to make scheduled debt payments. However, our ability to generate sufficient cash flow from operations of the Company and to utilize other methods to make scheduled payments will depend on a range of economic, competitive and business factors, many of which are outside of our control. There can be no assurance that these sources will be adequate. If we are unable to service our indebtedness and fund our operations, we will be forced to reduce or delay capital expenditures, seek additional capital, sell assets or refinance our indebtedness. Any such action may not be successful and we may be unable to service our indebtedness and fund our operations, which could have a material adverse effect on our business, financial condition or results of operations. Additionally, we may not be able to refinance existing debt on favorable or comparable terms.
The agreements that govern our indebtedness impose restrictions that may affect our ability to operate our businesses.
The agreements that govern our indebtedness contain various affirmative and negative covenants that may, subject to certain significant exceptions, restrict the ability of certain of our subsidiaries to incur debt and the ability of us and certain of our subsidiaries to, among other things, have liens on our property, and/or merge or consolidate with any other person or sell or convey certain of our assets to any one person, engage in certain transactions with affiliates and change the nature of our business. In addition, the agreements also require us to comply with certain financial covenants, including financial ratios. Our ability and the ability of our subsidiaries to comply with these provisions may be affected by events beyond our control. Failure to comply with these
25

Table of Contents
covenants could result in an event of default, which, if not cured or waived, could accelerate our repayment obligations and could result in a default and acceleration under other agreements containing cross-default provisions. Under these circumstances, we might not have sufficient funds or other resources to satisfy all of our obligations.
Risks Relating to the Spin-off of Embecta Corp.
On April 1, 2022, we completed the spin-off of Embecta Corp. (Embecta) (NASDAQ: EMBC), which holds our former Diabetes Care business and is now one of the world’s largest pure-play diabetes management companies in the world. The spin-off is intended to be a tax-free transaction for U.S. federal income tax purposes. If any facts, assumptions, representations, and undertakings from BD and Embecta regarding the past and future conduct of their respective businesses and other matters are incorrect or not otherwise satisfied, the spin-off may not qualify for tax-free treatment, which could result in significant U.S. federal income tax liabilities for BD and its shareholders.
General Business Risks
We cannot guarantee that any of our strategic acquisitions, investments or alliances will be successful.
We seek to supplement our internal growth through strategic acquisitions, investments and alliances. Such transactions are inherently risky, and the integration of any newly-acquired business requires significant effort and management attention. The success of any acquisition, investment or alliance may be affected by a number of factors, including our ability to properly assess and value the potential business opportunity or to successfully integrate any business we may acquire into our existing business. There can be no assurance that any past or future transaction will be successful.
Natural disasters, war and other events beyond our control could disrupt our business and adversely affect our future revenues and operating income.
Natural disasters, such as hurricanes, tornadoes, windstorms, earthquakes, wildfires, floods and other extreme weather events (including those caused by climate change), war, global health crises, terrorism, social or political unrest, labor disruptions and international conflicts and other events beyond our control, and actions taken by the U.S. and other governments or by our customers or suppliers in response to such events, could cause significant economic disruption and political and social instability in the U.S. and areas outside of the U.S. in which we operate. These events could result in decreased demand for our products, adversely affect our manufacturing and distribution capabilities, or increase the costs for or cause interruptions in the supply of materials from our suppliers.

26

Table of Contents
Information About our Executive Officers
The following is a list of the executive officers of BD, their ages and all positions and offices held by each of them during the past five years. There is no family relationship between any executive officer or director of BD.
Name Age Position
Thomas E. Polen 51 Chairman since April 2021; Chief Executive Officer since January 2020; President since April 2017; Chief Operating Officer from October 2018 to January 2020; and Executive Vice President and President - Medical Segment from October 2014 to April 2017.
Richard Byrd 57 Executive Vice President and President, Interventional Segment since September 2022; Worldwide President, BD Medication Delivery Solutions from March 2019 to September 2022; Worldwide President, Preanalytical Systems from December 2016 to February 2019.
Christopher J. DelOrefice 53 Executive Vice President and Chief Financial Officer since September 2021; Vice President, Investor Relations, Johnson & Johnson from August 2018 to September 2021; and Chief Financial Officer, North America Hospital Medical Devices, Johnson & Johnson from June 2017 to August 2018.
Antoine C. Ezell 55
Executive Vice President, President of the Americas and Chief Marketing Officer since October 2020; Executive Vice President and Chief Marketing Officer from January 2020 to October 2020; Vice President, Connected Care and Insulins, Eli Lilly and Company from January 2019 to January 2020; and prior thereto, Vice President, Enterprise Capabilities and Solutions, Eli Lilly; Chief Marketing Officer, Elanco Animal Health; and Chief Customer Officer, Eli Lilly.
Michael Feld 44 Executive Vice President and President, Life Sciences since August 2024; President of Hach (Veralto Corporation) from September 2023 to August 2024; Senior Vice President and General Manager of Danaher Corporation from June 2022 to September 2023; and President of Mammotome (Danaher Corporation) from January 2019 to September 2022.
Michael Garrison 56 Executive Vice President and President, Medical Segment since September 2022; Worldwide President, BD Medication Management Solutions from March 2020 to September 2022; Worldwide President, BD Surgery from December 2018 to March 2020; Vice President and General Manager Worldwide Infusion Systems from July 2016 to December 2018.
Roland Goette 62 Executive Vice President and President, EMEA since May 2017.
Pavan Mocherla 55 Executive Vice President and President, Greater Asia since July 2022; Country General Manager, South Asia/Managing Director from December 2017 to June 2022.
Shana Neal 59 Executive Vice President and Chief People Officer since April 2022; Chief Human Resources Officer of Owens & Minor from April 2018 to March 2022.
Michelle Quinn 56 Executive Vice President and General Counsel since April 2023; Senior Vice President, Deputy General Counsel and Chief Ethics and Compliance Officer from February 2022 to April 2023; Senior Vice President, Chief Ethics & Compliance Officer, Chief Regulatory Counsel from May 2019 to January 2023; Senior Vice President, Chief Compliance Officer from February 2019 to May 2019.
David Shan 54 Executive Vice President and Chief Integrated Supply Chain Officer since January 2023; Executive Vice President and Chief Quality Officer from March 2020 to August 2023; Senior Vice President, Global Supply Chain from May 2018 to August 2020.

27

Table of Contents
Item 1B. Unresolved Staff Comments.
None.
Item 1C. Cybersecurity.
Risk Management and Strategy
BD’s cybersecurity risk management program is focused on maintaining the confidentiality, integrity and availability of BD products, manufacturing and distribution operational technology (“OT”), enterprise IT and BD data. We incorporate cybersecurity risk management into our systems and processes, which we strive to align with multiple industry-leading cybersecurity standards, including the Joint Security Plan issued by the Health Sector Coordinating Council for BD products and guidelines issued by the National Institute of Standards and Technology (NIST) for our manufacturing and distribution OT and enterprise IT.
Our commitment to cybersecurity includes a total life cycle approach to protecting BD products, manufacturing and distribution OT, enterprise IT and BD data. Using various tools and techniques, we proactively monitor for suspicious activity and perform risk assessments (including independent third-party risk assessments), penetration testing and vulnerability scanning to identify potential threats and vulnerabilities. We also collaborate with government and industry leaders to gather and share cybersecurity threat intelligence. We provide mandatory annual cybersecurity awareness training for our 70,000+ associates, and we send phishing simulation emails monthly to all associates who use a BD email address and an assigned computing device. We also use tools to monitor unintentional sharing of personal, confidential and proprietary information. Our cybersecurity risk management program includes a documented incident response and critical incident management plan to identify, assess and manage the potential impact of cybersecurity threats or vulnerabilities and prioritize risk mitigation and/or remediation measures to safeguard BD products, manufacturing and distribution OT, enterprise IT and BD data.
We strive to align BD Information Security policies and procedures with industry best practices, including the NIST Cybersecurity Framework, International Organization for Standardization (“ISO”)/International Electrotechnical Commission (IEC) 27001:2022 standards for information security, Underwriters Laboratories (“UL”) 2900-1 Cybersecurity Standard for Medical Devices, and U.S. Food and Drug Administration’s pre-market and post-market guidance for cybersecurity in medical devices. In 2022, BD achieved ISO/IEC 27001:2022 certification at the enterprise level, demonstrating that BD’s Information Security Management System (ISMS) conforms to internationally recognized cybersecurity standards. In July 2024, BD engaged a third-party auditor to complete its second enterprise-level annual surveillance audit for ISO 27001, which determined that BD continues to meet these rigorous standards. These policies and procedures establish processes for handling data, assets, systems and other technology resources to help protect BD products, manufacturing and distribution OT, enterprise IT and BD data.
We also incorporate cybersecurity risk management into our Enterprise Risk Management (“ERM”) program. Through our ERM program, we identify, assess and manage a broad range of risks across our businesses, regions and functions, and we align our risk management efforts with our corporate strategy. Our enterprise IT, manufacturing and distribution OT, third-party and product cybersecurity risks are each assessed as part of our ERM program. As part of our cybersecurity risk management program, we engage a range of third-party experts each year, including advisors, consultants and auditors, to evaluate and enhance our program through security attestations and certifications, maturity assessments and security testing. We also engage third parties for staff augmentation to strengthen our cybersecurity program through additional dedicated resources. In addition, we actively engage with intelligence agencies, law enforcement, and advocacy and industry groups.
We also identify, assess and manage risks associated with our use of third-party service providers and maintain a third-party risk management program that monitors third-party cybersecurity risk throughout the procurement lifecycle—from planning and sourcing through relationship conclusion. This program includes supplier cybersecurity vetting at the time of engagement, cybersecurity risk assessments and cybersecurity vulnerability monitoring. Our third-party risk management program is aligned with NIST and ISO/IEC frameworks and is focused on continuous improvement through intelligence sharing with industry groups.
28

Table of Contents
There can be no assurance that such measures will be sufficient to prevent, mitigate or remediate cybersecurity incidents or breaches. Although we have experienced cyberattacks as discussed in “Item 1A, Risk Factors” above, based on the information available as of the date of this Annual Report on Form 10-K, we are not aware of any risks from cybersecurity threats, that have materially affected or are reasonably likely to materially affect BD. Despite our efforts in implementing and maintaining our cybersecurity risk management program, there can be no assurance that we, or the third parties with which we interact, will not experience a cybersecurity incident or breach in the future that may materially affect us. For further discussion of how our business, results of operations, and financial condition could be materially adversely affected by risks from cybersecurity threats, see “Item 1A, Risk Factors.”
Governance
The Board and its committees provide oversight of our ERM program, including our cybersecurity risk management program and the protection and resilience of BD products, manufacturing and distribution OT, enterprise IT and BD data. In addition, our management periodically conducts cybersecurity crisis simulations with the full Board to raise awareness of cybersecurity risks and enhance our incident preparedness. We also provide Board members the opportunity to take a cybersecurity training course through an external service provider. The Board delegates oversight of our cybersecurity risk management program to the Audit Committee and the Quality and Regulatory Committee (QRC). The Audit Committee regularly reviews our cybersecurity risk management program with respect to manufacturing and distribution OT and enterprise IT, and the QRC reviews our product cybersecurity program.
Our cybersecurity risk management program is led by our Chief Information Security Officer (“CISO”), whose organization is responsible for identifying, assessing and managing risks from cybersecurity threats. Our CISO has over 20 years of experience leading information security, data risk management, application/system development and engineering teams at multiple large, global and publicly traded companies—including several Fortune 500 companies. Our CISO holds Certified Information Systems Security Professional (“CISSP”), Certified Information Security Manager (“CISM”), Certified Information Privacy Professional (“CIPP”) and Security+ certifications and contributes to healthcare industry working groups, most recently serving as chair of the Health Information Sharing and Analysis Center (the “HISAC”) Information Security Risk Management Working Group. Our CISO reports to our Chief Information Officer (CIO), who has overall responsibility for the cybersecurity risk management program and organization. Our CIO has more than 25 years of experience in information technology, business transformation, cybersecurity and technology solutions, including leadership roles at multiple large, global and publicly traded companies—including several Fortune 500 companies. Our Vice President, Research and Development, Product Security (“VP of Product Security”) also supports our cybersecurity risk management program by leading a team of product security professionals focused on implementing security by design, security in use and product end of life strategies across our portfolio of software-based products. Our VP of Product Security has more than 15 years of experience in the medical device industry, including at another publicly traded company managing product security. Our VP of Product Security has received training from the SANS Institute and contributes to healthcare industry groups such as the Health Sector Coordinating Counsel – Joint Cybersecurity Working Group.
Our CISO is supported by and is a member of our Cybersecurity Strategy and Risk Committee (“CSRC”), which is a management-level governance body for oversight of all of our cybersecurity risk. Our VP of Product Security is also a member of the CSRC. On a quarterly basis, our CSRC receives information from our CISO regarding BD’s enterprise IT, manufacturing and distribution OT and product security programs, including the Company’s strategy and progress on key initiatives. We also have an executive-level Enterprise Risk Committee (ERC) that oversees our ERM program and aims to create an enterprise-wide culture that promotes open discussion regarding risk and opportunities and integrates effective risk management into our goals and objectives. As part of integrating cybersecurity risk management into our ERM program, our ERC receives updates from our CIO and CISO on BD’s cybersecurity risk management strategy and program on a regular basis.
29

Table of Contents
In addition to our CSRC and our ERC, we have established processes providing for the escalation of certain cybersecurity incidents and breaches. We maintain a global response plan that sets forth a detailed incident management and reporting protocol designed to respond to cybersecurity incidents and breaches appropriately and efficiently. Our operational team is responsible for communicating the impact and status of certain cybersecurity incidents and breaches to senior management, including the CISO, based on its assessment of the significance of the cybersecurity incident or breach. We also have a committee consisting of senior members of our management, including our CIO and CISO, to evaluate cybersecurity incidents and breaches reported to the committee by our CISO on an ad-hoc basis for potential material impacts on BD, including its financial condition and results of operations, and assess BD’s public disclosure obligations. The CIO, CISO and other members of the committees are informed about the status, effectiveness and risks associated with our cybersecurity risk management program through their management of and participation in the cybersecurity risk management processes, policies and operations described above.
Our CIO and CISO provide updates to the Audit Committee, and our VP of Product Security provides updates to the QRC, multiple times per year regarding BD’s cybersecurity risk management program, including the results of third-party assessments, progress towards cybersecurity goals and objectives, product cybersecurity matters, third-party risk management, regulatory compliance and other topics as needed. We also have processes by which certain cybersecurity incidents and breaches are escalated and reported to the Board of Directors or a Board committee, as appropriate, based on our management’s assessment of risk.
Item 2.    Properties.
BD’s executive offices are located in Franklin Lakes, New Jersey. As of September 30, 2024, BD owned or leased 302 facilities throughout the world, comprising approximately 26,555,343 square feet of manufacturing, warehousing, administrative, and research facilities. The U.S. facilities, including those in Puerto Rico, comprise approximately 7,962,022 square feet of owned and 4,537,419 square feet of leased space. The international facilities comprise approximately 10,547,043 square feet of owned and 3,508,859 square feet of leased space. Sales offices and distribution centers included in the total square footage are also located throughout the world.
Operations in each of BD’s business segments are conducted at both U.S. and international locations. Particularly in the international marketplace, facilities often serve more than one business segment and are used for multiple purposes, such as administrative/sales, manufacturing and/or warehousing/distribution. BD generally seeks to own its manufacturing facilities, although some are leased.
BD believes that its facilities are of good construction and in good physical condition, are suitable and adequate for the operations conducted at those facilities, and are, with minor exceptions, fully utilized and operating at normal capacity.
The U.S. facilities are located in Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Maryland, Massachusetts, Nebraska, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Washington D.C., Washington, Wisconsin, and Puerto Rico.
The international facilities are as follows:
Europe, Middle East, Africa, which includes facilities in Austria, Belgium, Bosnia, the Czech Republic, Denmark, Egypt, England, Finland, France, Germany, Ghana, Greece, Hungary, Ireland, Israel, Italy, Kenya, Luxembourg, Netherlands, Norway, Poland, Portugal, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, and the United Arab Emirates.
Greater Asia, which includes facilities in Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, New Zealand, Pakistan, the Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.
- Latin America & Caribbean, which includes facilities in Argentina, Barbados, Brazil, Chile, Colombia, the Dominican Republic, Mexico, Peru and Uruguay.
- Canada.
30

Table of Contents

Item 3.    Legal Proceedings.
Information with respect to certain legal proceedings is included in Note 6 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data, and is incorporated herein by reference.
Item 4.    Mine Safety Disclosures.
Not applicable.
31

Table of Contents
PART II
Item 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
BD’s common stock is listed on the New York Stock Exchange under the symbol "BDX”. As of November 1, 2024, there were approximately 10,012 shareholders of record.
The table below sets forth certain information regarding BD’s purchases of its common stock during the fiscal quarter ended September 30, 2024.
Period Total Number of
Shares
Purchased (1)
Average
Price
Paid
per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs (2)
Maximum Number
of Shares that
May Yet be
Purchased Under the
Plans or Programs (2)
July 1-31, 2024 1,164  $ 240.58  —  6,681,777 
August 1-31, 2024 249  232.02  —  6,681,777 
September 1-30, 2024 —  —  —  6,681,777 
Total 1,413  $ 239.07  —  6,681,777 
(1)Includes 1,413 shares purchased during the quarter in open market transactions by the trust relating to BD’s Deferred Compensation and Retirement Benefit Restoration Plan and 1996 Directors’ Deferral Plan.
(2)Represents shares available under a repurchase program authorized by the Board of Directors on November 3, 2021, for 10 million shares, for which there is no expiration date.
Item 6.    (Reserved)
32

Table of Contents

Item 7.     Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following commentary should be read in conjunction with the consolidated financial statements and accompanying notes presented in this report. Within the tables presented throughout this discussion, certain columns may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. References to years throughout this discussion relate to our fiscal years, which end on September 30.
Company Overview
Description of the Company and Business Segments
Becton, Dickinson and Company (“BD”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's organizational structure is based upon three principal business segments, BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”).
BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. We organize our operations outside the United States as follows: EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, Australia and New Zealand); Latin America (which includes Mexico, Central America, the Caribbean and South America); and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East and Africa (collectively referred to below as “EMA”), as well as, Latin America and certain countries within Greater Asia.
Strategic Objectives
BD remains focused on delivering durable growth, creating shareholder value and making appropriate investments for the future. BD 2025, our vehicle for value creation, is anchored in three key pillars: grow, simplify and empower. BD's management team aligns our operating model and investments with these key strategic pillars through continuous focus on the following underlying objectives:
Grow
Accelerating innovation in smart devices, robotics, analytics, and artificial intelligence in order to enable new care settings, improve outcomes, streamline care workflows, and reduce costs within healthcare settings;
Focusing on a strong portfolio of core leading products, solutions and services that deliver greater benefits to patients, healthcare workers and researchers;
Investing in research and development that leads to and expands category leadership, as well as results in a robust product pipeline;
Leveraging our global scale in order to provide equitable access to affordable medical technologies around the world, including in under-resourced markets;
Supplementing our internal growth through strategic acquisitions in faster growing market segments; and
Focusing on cash management and an efficient capital structure in order to drive balance sheet productivity and strong shareholder returns.

Simplify
Driving operating effectiveness and margin expansion through deployment of our BD Excellence program to increase factory productivity and asset efficiencies;
33

Table of Contents
Reducing complexity, increasing agility and improving customer experience by rationalizing our product portfolio, as well as by simplifying and optimizing our architecture and operating model;
Making strategic investments that prioritize a culture of quality and our quality management system to ensure we are a best-in-class, proactive quality-driven organization;
Enhancing customer experiences through the digitalization of internal processes and go-to-market approaches;
Collaborating across our supply chain to responsibly source materials and goods, as well as to reduce environmental impacts; and
Continuing our investments in an enterprise-wide renewable energy strategy to create more resilient operations.
Empower
Fostering a purpose-driven culture with a focus on positive impact to all stakeholders–customers, patients, employees, shareholders and communities;
Cultivating an inclusive work environment that welcomes and celebrates diverse backgrounds and perspectives;
Growing and enabling talent through training, development and reskilling strategies; and
Driving sustainability initiatives within our organizational units to support enterprise-wide collaboration towards our sustainability strategy.
In assessing the outcomes of these strategies as well as BD’s financial condition and operating performance, management generally reviews forecast data, monthly actual results, including segment sales, and other similar information. We also consider trends related to certain key financial data, including gross profit margin, selling and administrative expense, investment in research and development, return on invested capital, and cash flows.
Acquisition of Edwards Lifesciences’ Critical Care Product Group
On September 3, 2024, we completed the acquisition of Edwards Lifesciences’ Critical Care product group (“Critical Care”), which we renamed as BD Advanced Patient Monitoring (“Advanced Patient Monitoring”), for total consideration of $3.911 billion. Advanced Patient Monitoring is a global leader in advanced monitoring solutions that expands BD’s portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline that complement our existing technologies serving operating rooms and intensive care units.
BD reports the results associated with Advanced Patient Monitoring’s product offerings as a separate organizational unit within our Medical segment and additional disclosures relating to this acquisition are provided in Notes 8, 11 and 16 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data.
BD’s Spin-Off of Diabetes Care and Sale of Surgical Instrumentation Platform
In August 2023, we completed the sale of the Interventional segment's Surgical Instrumentation platform. The historical financial results for this platform have not been classified as a discontinued operation.
In April 2022, we completed the spin-off of our former Diabetes Care business as a separate publicly traded company. The historical results of the Diabetes Care business that was contributed in the spin-off were reflected as discontinued operations in our consolidated financial statements.
Additional disclosures regarding the sale and spin-off are provided in Note 2 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data.
34

Table of Contents
Key Trends Affecting Results of Operations
Our operations, supply chain, suppliers and customers are exposed to various global macroeconomic factors and we continually evaluate macroeconomic conditions to assess their potential impact to our operations and financial results. Macroeconomic factors which affected our operations and impacted results in fiscal year 2024 included the following:
As anticipated, market dynamics in China, such as volume-based procurement programs (“VoBP”) and the government’s focus to improve compliance of healthcare practitioners, had an adverse impact on our results of operations and these dynamics could continue to unfavorably impact our results of operations.
As is further discussed below, our labor costs were generally higher in our fiscal year 2024 compared with the prior-year period.
We have experienced, and may continue to experience, temporary shortages in supply of certain materials or components that are used in our products. The stable flow of global transport is critical to our operations and as such, events affecting the flow of logistics around the globe may adversely impact our supply chain and distribution channels. In general, major disruptions in the sourcing, manufacturing and distribution of our products could adversely impact our results of operations.
In addition, current healthcare delivery has transitioned more care from acute to non-acute settings and has increased focus on chronic disease management; this transition has placed additional financial pressure on hospitals and the broader healthcare system. Healthcare institutions may take actions to mitigate any persistent pressures on their budgets and such actions could impact the future demand for our products and services. Additionally, a deterioration of staffing levels within healthcare systems may affect the prioritization of healthcare services, which could also impact the demand for certain of our products. Also, reductions or delays in governmental research funding and/or higher interest rates could cause customers for our instruments and reagents to delay or forgo purchases of these products.
Certain geopolitical conditions, including the evolving situations in Ukraine, the Middle East and Asia, may impact global macroeconomic conditions, including those discussed above. While these geopolitical conditions have not materially impacted our results of operations to date, the continuation and/or an escalation of these evolving situations may weaken the global economy and could result in additional inflationary pressures and supply chain constraints, including the unavailability and cost of energy.
We continue to invest in research and development, strategic tuck-in acquisitions, geographic expansion, and new product programs to drive further revenue and profit growth. Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business (including strategic geographical expansion), and develop innovative new products, as well as continue to improve operating efficiency and organizational effectiveness.
We have been mitigating the impacts of the macroeconomic and other factors discussed above through various strategies which leverage our procurement, logistics and manufacturing capabilities. However, there can be no assurance that we will be able to effectively mitigate these pressures in future periods and an inability to offset these pressures through our strategies, at least in part, could adversely impact our results of operations. Due to the significant uncertainty that exists relative to the duration and overall impact of the macroeconomic and other factors discussed above, our future operating performance, particularly in the short-term, may be subject to volatility. The impacts of macroeconomic and other conditions on our business, results of operations, financial condition and cash flows are dependent on certain factors, including those discussed in Part I, Item 1A. Risk Factors.
35

Table of Contents
Summary of Financial Results
Worldwide revenues in 2024 of $20.178 billion increased 4.2% from the prior-year period. This increase reflected the following impacts:
Increase (decrease) in current-year revenues
Volume/other (a) 4.2  %
Pricing 0.7  %
Foreign currency impact (0.1) %
Impact due to sale of Surgical Instrumentation platform (0.7) %
Acquisition of Advanced Patient Monitoring 0.4  %
Other (b) (0.3) %
Increase in revenues from the prior-year period
4.2  %
(a)    Volume/other includes revenues attributable to products, services and licensing.
(b)    Represents the recognition of accruals resulting from recent developments relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to the current fiscal year. Additional disclosures regarding these legislative and legal matters are provided in Notes 6 and 8 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data.
Our financial position remains strong, with cash flows from continuing operating activities totaling $3.844 billion in 2024. At September 30, 2024, we had $2.301 billion in cash and equivalents and short-term investments, including restricted cash. We continued to return value to our shareholders in the form of dividends and during fiscal year 2024, we paid cash dividends to common shareholders of $1.100 billion.
Each reporting period, we face currency exposure that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. The fiscal year 2024 impact of foreign currency translation on our revenues is provided above and the impact on our earnings is provided further below. We evaluate our results of operations on both a reported and a foreign currency-neutral basis, which excludes the impact of fluctuations in foreign currency exchange rates. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Foreign currency-neutral ("FXN") information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a foreign currency-neutral basis as one measure to evaluate our performance. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. generally accepted accounting principles ("GAAP"). Results on a foreign currency-neutral basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.
Results of Operations
Updates to Financial Results Reported in Earnings Release
On November 7, 2024, we furnished a Current Report on Form 8-K that included as an exhibit a press release announcing our financial results for the fourth fiscal quarter and the fiscal year ended September 30, 2024 (the “Earnings Release”). On November 22, 2024 and subsequent to furnishing the Earnings Release, we received the Dispensing Warning Letter, as more fully discussed under Item 1. Business— Regulation—FDA
36

Table of Contents
Warning Letters. A charge of $28 million to recognize our currently estimated liability for future costs expected to be incurred to address the non-conformities identified in the Dispensing Warning Letter was recorded to Cost of products sold for the three-month period and fiscal year ended September 30, 2024. The charge, which is included in the “Specified Items” section below, impacted our financial results for the fiscal year ended September 30, 2024, included in this Annual Report on Form 10-K, as follows:
Cost of product sold (from $11.025 billion reported in the Earnings Release to $11.053 billion);
Operating Income (from $2.425 billion reported in the Earnings Release to $2.397 billion);
Net Income from Continuing Operations (from $1.726 billion reported in the Earnings Release to $1.705 billion); and
Diluted Earnings per Share from Continuing Operations (from $5.93 reported in the Earnings Release to $5.86).
Medical Segment
The following summarizes Medical revenues by organizational unit:
        2024 vs. 2023 2023 vs. 2022
(Millions of dollars) 2024 2023 2022 Total
Change
Estimated
FX
Impact
FXN Change Total
Change
Estimated
FX
Impact
FXN Change
Medication Delivery Solutions $ 4,429  $ 4,293  $ 4,308  3.2  % (0.1) % 3.3  % (0.3) % (1.9) % 1.6  %
Medication Management Solutions 3,297  2,980  2,533  10.7  % 0.2  % 10.5  % 17.6  % (1.0) % 18.6  %
Pharmaceutical Systems 2,273  2,229  2,001  2.0  % 0.2  % 1.8  % 11.4  % (1.7) % 13.1  %
Advanced Patient Monitoring 74  —  —  NM NM NM NM NM NM
Total Medical revenues $ 10,074  $ 9,502  $ 8,841  6.0  % —  % 6.0  % 7.5  % (1.6) % 9.1  %
"NM" denotes that the percentage change is not meaningful.
The Medical segment’s revenue growth in 2024 primarily reflected the following.
Strong global demand for the Medication Delivery Solutions unit’s Vascular Access Management portfolio, as well as strong U.S. demand for medication delivery products, partially offset by the impact of unfavorable market dynamics in China.
Double-digit growth in sales of infusion systems, as well as higher utilization of infusion sets within the Medication Management Solutions unit, partially offset by an unfavorable comparison to stronger placements of dispensing solutions in 2023.
Double-digit growth in sales of the Pharmaceutical Systems unit’s prefillable solutions in the biologic drug category, partially offset by customer order patterns relating to other drug categories.
Overall Medical segment revenue growth in 2024 also reflected the acquired Advanced Patient Monitoring unit’s sales beginning on September 3, 2024.

The Medical segment’s revenue growth in 2023 primarily reflected the following.
Strong global sales of catheters and other vascular care products in the Medication Delivery Solutions unit were partially offset by the impact of VoBP in China and lower COVID vaccination-related revenues in 2023 compared with these revenues in 2022.
Strong performance of the Medication Management Solutions unit’s pharmacy automation portfolio, including Parata Systems, which we acquired in fiscal year 2022, and our BD Rowa™ technologies, as well as strong growth in sales of dispensing systems. Revenue growth attributable to the unit’s recent acquisitions was approximately 9.3% in 2023.
37

Table of Contents
Continued strong demand for the Pharmaceutical Systems unit’s prefillable solutions in high-growth markets such as the biologic drug category.
Medical segment operating income was as follows:
(Millions of dollars) 2024 2023 2022
Medical segment operating income $ 2,742  $ 1,967  $ 2,215 
Segment operating income as % of Medical revenues 27.2  % 20.7  % 25.1  %


The Medical segment's operating income as a percentage of revenues in 2024 and 2023, compared with the prior-year periods, reflected the following:
The Medical segment’s higher gross profit margin in 2024 compared with 2023 primarily reflected the following:
A favorable comparison to gross margin in 2023, which was impacted by $653 million of charges related to estimated future costs associated with the Medication Management Solutions unit’s remediation efforts related to AlarisTM infusion pumps, as well as lower manufacturing costs, which resulted from continuous improvement projects and other productivity initiatives that enhanced the efficiency of our operations; partially offset by
An unfavorable impact of $59 million due to a fair value step-up adjustment relating to Advanced Patient Monitoring's inventory on the acquisition date, higher raw material and labor costs, as well as unfavorable foreign currency translation.
The Medical segment’s lower gross profit margin in 2023 compared with 2022 primarily reflected the following:
The $653 million of charges noted above related to product remediation efforts compared with charges in 2022 related to the same efforts of $72 million. The fiscal year 2023 charge impacted gross margin by approximately 6.9%.
Higher raw material, labor and freight costs, as well as unfavorable foreign currency translation; partially offset by
Lower manufacturing costs resulting from continuous improvement projects and pricing.
Lower selling and administrative expense as a percentage of revenues in 2024 compared with 2023 primarily reflected revenue growth that outpaced spending and lower shipping costs. Selling and administrative expense as a percentage of revenues in 2023 was lower compared with 2022 due to lower selling and shipping costs.
Research and development expense as a percentage of revenues in 2024 was lower compared with 2023, and in 2023 compared with 2022, which reflected revenue growth that outpaced project spending.


38

Table of Contents
Life Sciences Segment
The following summarizes Life Sciences revenues by organizational unit:
        2024 vs. 2023 2023 vs. 2022
 (Millions of dollars)
2024 2023 2022 Total
Change
Estimated
FX
Impact
FXN Change Total
Change
Estimated
FX
Impact
FXN Change
Integrated Diagnostic Solutions $ 3,679  $ 3,624  $ 4,185  1.5  % (0.1) % 1.6  % (13.4) % (2.0) % (11.4) %
Biosciences 1,512  1,509  1,379  0.2  % —  % 0.2  % 9.4  % (2.2) % 11.6  %
Total Life Sciences revenues $ 5,191  $ 5,133  $ 5,564  1.1  % —  % 1.1  % (7.8) % (2.1) % (5.7) %

The Life Sciences segment’s revenue growth in 2024 primarily reflected the following:
Strong growth in sales of the Integrated Diagnostic Solutions unit’s specimen management portfolio, partially offset by an unfavorable comparison to higher respiratory testing revenues in 2023, including COVID-19-only diagnostic testing revenues.
Strong demand for the Biosciences unit’s clinical reagents, offset by a decline in sales of the unit’s instrumentation due to a decline in life science research funding, primarily in the United States and China.
The Life Sciences segment's revenues in 2023 primarily reflected the following:
Revenues related to COVID-19-only diagnostic testing on the BD VeritorTM Plus and BD MaxTM Systems in the Integrated Diagnostic Solutions unit of $73 million compared with revenues in 2022 of $511 million and an unfavorable comparison to stronger sales in 2022 of the Integrated Diagnostic Solutions unit’s combination influenza/COVID-19 testing assays, as well as destocking of specimen management products by U.S. distributors in 2023; partially offset by
Growth in the Integrated Diagnostic Solutions unit’s microbiology platform and growth attributable to molecular diagnostic platforms which leveraged our larger installed base of BD MAXTM instruments.
Strong growth in sales of the Biosciences unit’s reagents and instruments, including recently launched research instruments.
Life Sciences segment operating income was as follows:
(Millions of dollars) 2024 2023 2022
Life Sciences segment operating income $ 1,595  $ 1,585  $ 1,710 
Segment operating income as % of Life Sciences revenues 30.7  % 30.9  % 30.7  %

The Life Sciences segment's operating income as a percentage of revenues in 2024 and 2023, compared with the prior-year periods, reflected the following:
The Life Sciences segment’s lower gross profit margin in 2024 compared with 2023 primarily reflected higher raw material and labor costs, as well as declines in respiratory illness-related revenues and unfavorable foreign currency translation, partially offset by lower manufacturing costs resulting from continuous improvement projects and other productivity initiatives.
The Life Sciences segment’s higher gross profit margin in fiscal year 2023 compared with 2022 primarily reflected the following:
39

Table of Contents
Favorable impacts in 2023 from price and continuous improvement projects in our manufacturing facilities; partially offset by
The decline in COVID-19-only testing revenues and a decline in licensing income compared with 2022, as well as higher raw material and labor costs in 2023.
Selling and administrative expense as a percentage of revenues in 2024 was higher compared with 2023, which primarily reflected lower costs in 2023. Lower selling and administrative expense as a percentage of revenues in 2023 compared with 2022 primarily reflected lower selling costs and efforts to contain certain administrative costs.
Lower research and development expense as a percentage of revenues in 2024 compared with 2023 primarily reflected the progression of current projects. Higher research and development expense as a percentage of revenues in 2023 compared with 2022, primarily reflected the decline in segment revenues in 2023 compared with the prior-year period.
Interventional Segment
The following summarizes Interventional revenues by organizational unit:
        2024 vs. 2023 2023 vs. 2022
 (Millions of dollars)
2024 2023 2022 Total
Change
Estimated
FX
Impact
FXN Change Total
Change
Estimated
FX
Impact
FXN Change
Surgery $ 1,492  $ 1,497  $ 1,400  (0.3) % (0.1) % (0.2) % 6.9  % (1.3) % 8.2  %
Peripheral Intervention 1,933  1,865  1,759  3.7  % (0.4) % 4.1  % 6.0  % (2.9) % 8.9  %
Urology and Critical Care 1,554  1,374  1,305  13.1  % (0.5) % 13.6  % 5.3  % (1.8) % 7.1  %
Total Interventional revenues $ 4,980  $ 4,736  $ 4,464  5.1  % (0.4) % 5.5  % 6.1  % (2.0) % 8.1  %

The Interventional segment’s revenue growth in 2024 primarily reflected the following:
Strong growth in sales across the Surgery unit’s advanced repair and reconstruction platforms, as well as its infection prevention products; the prior-year period’s revenues included $140 million attributable to the unit’s former Surgical Instrumentation platform, which was sold in the fourth quarter of fiscal year 2023.
Double-digit growth attributable to the Peripheral Intervention unit’s peripheral vascular disease platform, partially offset by a decline in sales of our oncology products due to customer ordering patterns and market dynamics in China.
Double-digit growth in sales of the Urology and Critical Care unit’s PureWickTM offerings and current-year licensing revenue.
The Interventional segment’s revenue growth in 2023 primarily reflected the following:
Double-digit growth in global sales of the Surgery unit’s advanced repair and reconstruction platforms, as well as strong growth in sales of biosurgery products, was partially offset by a decline in revenues attributable to the sale of the Surgical Instrumentation platform in the fourth quarter.
Growth driven by global market penetration of the Peripheral Intervention unit’s peripheral vascular disease platform was partially offset by the impact of planned strategic portfolio exits.
Continued strong demand for the Urology and Critical Care unit’s PureWickTM offerings in the acute and alternative care settings.
40

Table of Contents
Interventional segment operating income was as follows:
(Millions of dollars) 2024 2023 2022
Interventional segment operating income $ 1,420  $ 1,217  $ 1,081 
Segment operating income as % of Interventional revenues 28.5  % 25.7  % 24.2  %

The Interventional segment's operating income as a percentage of revenues in 2024 and 2023, compared with the prior-year periods, reflected the following:
The Interventional segment’s higher gross profit margin in 2024 compared with 2023 primarily reflected favorable impacts from product mix and pricing.
The Interventional segment’s gross profit margin was flat in 2023 compared with 2022, which primarily reflected:
Favorable impacts from price, continuous improvement projects, and a favorable comparison to the prior-year period, which was unfavorably impacted by certain purchase accounting adjustments; offset by
Unfavorable impacts of higher raw material, labor and freight costs.
Lower selling and administrative expense, as well as research and development expense, as percentages of revenues in 2024 compared with 2023, and in 2023 compared with 2022, primarily reflected revenue growth that outpaced spending.
Geographic Revenues
BD’s worldwide revenues by geography were as follows:
        2024 vs. 2023 2023 vs. 2022
(Millions of dollars) 2024 2023 2022 Total
Change
Estimated
FX
Impact
FXN Change Total
Change
Estimated
FX
Impact
FXN Change
United States $ 11,663  $ 11,113  $ 10,722  4.9  % —  4.9  % 3.7  % —  3.7  %
International 8,515  8,258  8,148  3.1  % (0.2) % 3.3  % 1.4  % (4.2) % 5.6  %
Total revenues $ 20,178  $ 19,372  $ 18,870  4.2  % (0.1) % 4.2  % 2.7  % (1.8) % 4.5  %

U.S. revenue growth in 2024 reflected strong sales in the Medical segment’s Medication Delivery Solutions and Medication Management Solutions units, as well as in the Interventional segment’s Urology and Critical Care unit.
U.S. revenue growth in 2023 was particularly driven by strong sales in the Medical segment’s Medication Management Solutions and Pharmaceutical Systems units and in the Life Sciences segment’s Biosciences unit, as well as by strong sales in the Interventional segment’s Surgery and Urology and Critical Care units. U.S. revenues in 2023 were unfavorably impacted by a decline in COVID-19-only diagnostic testing sales compared with 2022, as discussed further above.
International revenue growth in 2024 was driven by the Medical segment’s Pharmaceutical Systems unit, the Life Sciences segment’s Integrated Diagnostic Solutions unit and the Interventional segment’s Peripheral Intervention unit. International revenue growth in 2024 also reflected the unfavorable impact of a $62 million accrual which resulted from recent developments relating to the Italian government medical device pay back legislation and substantially relates to years prior to the current fiscal year. Additional disclosures regarding this matter are provided in Note 6 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data.
41

Table of Contents
International revenue growth in 2023 was particularly driven by strong sales in the Medical segment’s Medication Management Solutions and Pharmaceutical Systems units, and in the Life Sciences segment’s Biosciences unit, as well as by strong sales in the Interventional segment’s Surgery and Peripheral Intervention units. International revenues in 2023 were unfavorably impacted by a decline in COVID-19-only diagnostic testing sales compared with 2022, as discussed further above.
Emerging market revenues were as follows:
        2024 vs. 2023 2023 vs. 2022
(Millions of dollars) 2024 2023 2022 Total
Change
Estimated
FX
Impact
FXN Change Total
Change
Estimated
FX
Impact
FXN Change
Emerging markets $ 3,054  $ 2,966  $ 2,904  3.0  % (0.6) % 3.6  % 2.1  % (3.6) % 5.7  %
Emerging market revenue growth in 2024 primarily reflected strong sales in Latin America and in countries other than China within Greater Asia, partially offset by a decline in China driven by unfavorable market dynamics, as further discussed above. Emerging market revenue growth in 2023 was primarily driven by sales in Latin America, South Asia, and in China, despite unfavorable impacts to China revenues from volume-based procurement programs.

Specified Items
Reflected in the financial results for 2024, 2023 and 2022 were the following specified items:
(Millions of dollars) 2024 2023 2022
Integration costs (a)
$ 23  $ 67  $ 68 
Restructuring costs (a)
387  239  123 
Transaction costs (b)
48  —  — 
Financing costs (b)
(8) —  — 
Separation-related items (c)
13  14  20 
Purchase accounting adjustments (d)
1,503  1,434  1,431 
Product, litigation, and other items (e)
346  554  268 
European regulatory initiative-related costs (f)
104  139  146 
Impacts of debt extinguishment —  —  24 
Total specified items 2,416  2,448  2,082 
Less: tax impact of specified items 297  399  366 
After-tax impact of specified items $ 2,119  $ 2,050  $ 1,716 
 
(a)Represents amounts associated with restructuring and integration activities which are recorded in Integration, restructuring and transaction expense and are further discussed below.
(b)Represents transaction costs, which are recorded in Integration, restructuring and transaction expense, and financing impacts, which are recorded in Interest income and Interest expense, associated with the Advanced Patient Monitoring acquisition.
(c)Represents costs recorded to Other operating expense (income), net and incurred in connection with the separation of BD's former Diabetes Care business.
(d)Includes amortization and other adjustments related to the purchase accounting for acquisitions. BD’s amortization expense is recorded in Cost of products sold.
(e)Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain product liability and legal defense costs, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in 2024 was primarily recorded to Revenues
42

Table of Contents
and Other operating expense (income), net, and largely related to legislative and legal matters, as further discussed above in our geographic revenue discussion and further below in our discussion of Other operating expense (income), net. Additional disclosures regarding these legislative and legal matters are provided in Notes 6 and 8 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data. The amounts in 2024, 2023 and 2022 included net charges within Cost of products sold of $38 million, $653 million and $72 million, respectively, to record or adjust future costs estimated for product remediation efforts. The amounts in 2023 and 2022 also included pension settlement costs of $57 million and $73 million, respectively, which were recorded to Other expense, net. The amount in 2022 also includes a charge of $54 million related to a noncash asset impairment, which was recorded to Cost of products sold. The amounts in 2023 and 2022 additionally include certain amounts recorded to Other operating expense (income), net, which are detailed further below.
(f)Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.

Gross Profit Margin
The comparisons of gross profit margins in 2024 and 2023 with the prior-year periods reflected the following impacts:
  2024 2023
Gross profit margin % prior-year period 42.2  % 44.9  %
Impact of purchase accounting adjustments and other specified items 3.2  % (2.5) %
Operating performance 0.7  % 0.1  %
Foreign currency impact (0.9) % (0.3) %
Gross profit margin % current-year period 45.2  % 42.2  %

The favorable impact on gross margin from specified items in 2024 compared with 2023 reflected a favorable comparison to specified items recorded in 2023, which included $653 million of charges recorded in the Medical segment to adjust the estimate of future product remediation costs, as noted above, partially offset by an unfavorable impact of $59 million due to a fair value step-up adjustment recorded by the Medical segment in 2024 relating to Advanced Patient Monitoring's inventory on the acquisition date.
The impact of other specified items on gross margin in 2023 compared with 2022 reflected the $653 million of charges recorded in 2023 as noted above related to product remediation efforts, compared with charges in 2022 related to the same efforts of $72 million. The impact of other specified item in 2023 compared with 2022 additionally reflected a non-cash asset impairment charge of $54 million recorded by the Medical segment in 2022.
Operating performance in 2024 and 2023 reflected lower manufacturing costs resulting from our ongoing continuous improvement projects and other productivity initiatives, as well as a favorable impact from pricing. These favorable impacts to operating performance in 2024 were partially offset by higher raw material and labor costs and an unfavorable absorption impact of planned inventory reductions. Operating performance in 2023 was unfavorably impacted by higher raw material, labor and freight costs.
43

Table of Contents
Operating Expenses
Operating expenses in 2024, 2023 and 2022 were as follows:
        Increase (decrease) in basis points
(Millions of dollars) 2024 2023 2022 2024 vs. 2023 2023 vs. 2022
Selling and administrative expense $ 4,857  $ 4,719  $ 4,709 
% of revenues 24.1  % 24.4  % 25.0  % (30) (60)
Research and development expense $ 1,190  $ 1,237  $ 1,256 
% of revenues 5.9  % 6.4  % 6.7  % (50) (30)
Integration, restructuring and transaction expense $ 458  $ 313  $ 192 
Other operating expense (income), net $ 222  $ (210) $ 37 

Selling and administrative
Selling and administrative expense as a percentage of revenues in 2024 was lower compared with 2023, which primarily reflected higher revenues and lower shipping costs in the current-year period, partially offset by higher selling costs.
Lower selling and administrative expense as a percentage of revenues in 2023 compared with 2022 primarily reflected higher revenues in 2023 and favorable foreign currency translation, partially offset by higher selling costs in 2023, as well as an increase in our deferred compensation plan liability due to market performance. The investment gains on deferred compensation plan assets were recorded to Other expense, net.
Research and development
Lower research and development expense as a percentage of revenues in 2024 compared with 2023, and in 2023 compared with 2022, primarily reflected the progression of current projects and revenue growth that outpaced project spending. Spending in 2024, 2023 and 2022 reflected our continued commitment to invest in new products and platforms.
Integration, restructuring and transaction expense
Integration expense in 2024, 2023 and 2022 primarily included costs related to system integrations and our 2022 acquisition of Parata Systems. Restructuring expense in 2024, 2023 and 2022 primarily included restructuring costs related to simplification and other cost-saving initiatives. Transaction costs in 2024 included legal, advisory and other costs, relating to our agreement to acquire Advanced Patient Monitoring. For further disclosures regarding the costs relating to restructurings, refer to Note 12 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data.
Other operating expense (income), net
Other operating expense (income) in 2024, 2023 and 2022 included the following items which are further discussed in the Notes to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data:
44

Table of Contents
(Millions of dollars) 2024 2023 2022
Charge to accrue an estimated liability for the SEC investigation (see Note 6) $ 175  $ —  $ — 
Other amounts recorded for legal matters (see Note 6) 79  —  — 
Amounts recorded for product liabilities, including related defense costs (see Note 6) (36) 26  21 
Separation-related items 13  14  20 
Gain recognized on sale of business (see Note 2) —  (268) — 
Other (9) 18  (4)
Other operating expense (income), net $ 222  $ (210) $ 37 

Net Interest Expense
(Millions of dollars) 2024 2023 2022
Interest expense $ (528) $ (452) $ (398)
Interest income 163  49  16 
Net interest expense $ (364) $ (403) $ (382)
Higher interest expense in 2024 compared with 2023 primarily reflected higher overall interest rates on debt outstanding, as well as higher total debt outstanding at September 30, 2024 compared with September 30, 2023, which reflected debt issued in our third quarter of fiscal year 2024 to fund the cash consideration payable upon our acquisition of Advanced Patient Monitoring. Higher interest expense in 2023 compared with 2022 was largely attributable to the higher levels of commercial paper borrowings outstanding throughout 2023 and higher overall interest rates on debt outstanding. Additional disclosures regarding our financing arrangements and debt instruments are provided in Note 16 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data.
Higher interest income in 2024 compared with 2023, and in 2023 compared with 2022, primarily reflected higher overall interest rates and levels of cash on hand during the current-year periods, compared with the prior-year periods.
Income Taxes
The income tax rates for continuing operations in 2024, 2023 and 2022 were as follows:
2024 2023 2022
Effective income tax rate for continuing operations 15.0  % 7.9  % 8.3  %
Impact, in basis points, from specified items 150  (500) (500)

The effective income tax rate for continuing operations in 2024 compared with 2023 primarily reflected the impact of more favorable discrete items recorded in 2023. The effective income tax rate for continuing operations in 2023 compared with 2022 primarily reflected the impact of a remeasurement of deferred tax assets and liabilities upon the approval of a tax incentive.


45

Table of Contents
Net Income and Diluted Earnings per Share from Continuing Operations
Net income and diluted earnings per share from continuing operations in 2024, 2023 and 2022 were as follows:
2024 2023 2022
Net income from continuing operations (Millions of dollars) $ 1,705  $ 1,530  $ 1,635 
Diluted earnings per share from continuing operations $ 5.86  $ 5.10  $ 5.38 
Unfavorable impact-specified items $ 7.28  $ 7.11  $ 5.97 
(Unfavorable) favorable impact-foreign currency impact $ (0.56) $ (0.37) $ 0.14 
Financial Instrument Market Risk
We selectively use financial instruments to manage market risk, primarily foreign currency exchange risk and interest rate risk relating to our ongoing business operations. The counterparties to these contracts are highly rated financial institutions. We do not enter into financial instruments for trading or speculative purposes. Additional disclosures regarding our derivative instruments are provided in Note 14 to the consolidated financial statements contained in Item 8. Financial Statements and Supplementary Data.
Foreign Exchange Risk
BD and its subsidiaries transact business in various foreign currencies throughout Europe, Greater Asia, Canada and Latin America. We face foreign currency exposure from the effect of fluctuating exchange rates on payables and receivables relating to transactions that are denominated in currencies other than our functional currency. These payables and receivables primarily arise from intercompany transactions. We hedge substantially all such exposures, primarily through the use of forward contracts. We have also hedged the currency exposure associated with investments in certain foreign subsidiaries with instruments such as foreign currency-denominated debt and cross-currency swaps, which are designated as net investment hedges, as well as currency exchange contracts. In order to mitigate transactional foreign currency exposures resulting from anticipated intercompany purchases and sales, we have hedged a portion of this currency risk with certain instruments such as foreign exchange forward and option contracts, which are designated as cash flow hedges. We also face currency exposure that arises from translating the results of our worldwide operations, including sales, to the U.S. dollar at exchange rates that have fluctuated from the beginning of a reporting period. We did not enter into contracts to hedge cash flows against these foreign currency impacts in fiscal year 2024 or 2023.
Derivative financial instruments are recorded on our balance sheet at fair value. For foreign currency derivatives, market risk is determined by calculating the impact on fair value of an assumed change in foreign exchange rates relative to the U.S. dollar. Fair values were estimated based upon observable inputs, specifically spot currency rates and foreign currency prices for similar assets and liabilities.
With respect to the foreign currency derivative instruments outstanding at September 30, 2024 and 2023, the impact that changes in the U.S. dollar would have on pre-tax earnings was estimated as follows:
  Increase (decrease)
(Millions of dollars) 2024 2023
10% appreciation in U.S. dollar $ (143) $ (100)
10% depreciation in U.S. dollar $ 147  $ 100 
These calculations do not reflect the impact of exchange gains or losses on the underlying transactions that would substantially offset the results of the derivative instruments.



46

Table of Contents
Interest Rate Risk
When managing interest rate exposures, we strive to achieve an appropriate balance between fixed and floating rate instruments. We may enter into interest rate swaps to help maintain this balance and manage debt and interest-bearing investments in tandem, since these items have an offsetting impact on interest rate exposure. For interest rate derivative instruments, fair values are measured based upon the present value of expected future cash flows using market-based observable inputs including credit risk and interest rate yield curves. Market risk for these instruments is determined by calculating the impact to fair value of an assumed change in interest rates across all maturities. 
The impact that changes in interest rates would have on interest rate derivatives outstanding at September 30, 2024 and 2023, as well as the effect that changes in interest rates would have on our earnings or cash flows over a one-year period, based upon our overall interest rate exposure, were estimated as follows:
Increase (decrease) to fair value of interest rate derivatives outstanding Increase (decrease) to earnings or cash flows
(Millions of dollars) 2024 2023 2024 2023
10% increase in interest rates $ (12) $ (3) $ $
10% decrease in interest rates $ 12  $ $ (5) $ (2)

Liquidity and Capital Resources
Our strong financial position and cash flow performance have provided us with the capacity to accelerate our innovation pipeline through investments in research and development, as well as through strategic acquisitions. We believe that our available cash and cash equivalents, our ability to generate operating cash flow, and if needed, our access to borrowings from our financing facilities provide us with sufficient liquidity to satisfy our foreseeable operating needs. The following table summarizes our consolidated statement of cash flows in 2024, 2023 and 2022:
(Millions of dollars) 2024 2023 2022
Net cash provided by (used for) continuing operations